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ABSTRACT
Several independent observations suggest that cytotoxic T lymphocytes (CTL) are 
critical for the control of HIV infection. We have studied the adoptive transfer of 
CTL in three patients with aquired immunodeficiency syndrome (AIDS).
In the first patient, we examined the CD8+ T cell repertoire before and after the 
transfer of syngeneic lymphocytes from his uninfected sibling to confirm whether 
aberrations exist in the CTL repertoire during advanced HIV infection and to 
determine whether adoptive immunotherapy with lymphocytes can lead to sustained 
expansions of CD8+ cells. Repertoire analysis revealed baseline expansions in some 
TCR subsets. Following cell transfer, there were new changes in two V-beta families, 
one at 24 hours post-infusion and the other and after 28 days, post-infusion. This 
study demonstrated that expansion and transient restoration of both CD4+ and 
CD8+ T-cells can occur in vivo following sygeneic cell transfer and that maximal 
lymphocyte expansion occurring appears to be maximal around 4 weeks post­
infusion.
In the second and third patients, we studied the adoptive transfer of HIV-specific 
CTL clones. Despite substantial HIV-specific lytic activity in vitro, there were no 
significant changes in the virus load of patients following adoptive transfer. In one 
patient, we traced the fate of an infused clone using soluble MHC-peptide complexes 
and showed that cells were rapidly eliminated within hours of infusion, probably 
through apoptosis.
The use of CTL adoptive therapy in AIDS needs to be re-examined in light of these 
finding. Further trials of adoptive transfer of CTL should take into account the 
susceptibility of infused cells to in vivo apoptosis.
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CHAPTER ONE
Introduction
The work presented in this thesis is an attempt to determine the safety, feasibility 
and efficacy of transferring autologous or syngeneic T-lymphocytes to patients 
infected with human immunodeficiency virus - 1 (HIV). By studying the effects of 
autologous or syngeneic lymphocyte transfer, we also hope to define better the role 
of cytotoxic T lymphocytes (CTL) in the pathogenesis of and the protection from 
acquired immunodeficiency syndrome (AIDS), to develop better protocols for the 
large scale in vitro production of T-cells and to elucidate the basic immunology 
underlying adoptive CTL therapy for infectious diseases or cancer. It is neither 
possible to understand the pathogenesis of AIDS nor the biology of CTL adoptive 
transfer without a general understanding of the human immune system. Thus, this 
introduction begins with an overview of basic immunology, with particular 
reference to MHC Class I restricted CTL responses to viral infections. This is 
followed by a more comprehensive review of the role of CTL in HTV infection.
The Cellular Immune Response to Viral Infection
The human immune system consists of adaptive and non-adaptive responses. The 
human immune system has evolved to protect healthy cells from potentially harmful 
micro-organisms such as bacteria, fungi, viruses and parasites. In addition, the 
immune system continually monitors and eliminates host cells which have 
undergone transformation and express tumour antigens.
Non-adaptive or innate immunity consists of phylogenedcally primitive defense 
mechanisms which are common to both vertebrate and non-vertebrate organisms 
and which do not distinguish between a primary infection and subsequent infections 
(reviewed in (Medzhitov and Janeway 1997)). These mechanisms include external
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barriers such as skin, sweat and hair as well as internal circulating cells such as 
polymorphonuclear cells, macrophages and natural killer cells, all of which provide a 
rapid and first-line response to infectious pathogens. In contrast, vertebrate 
organisms are able to generate a second line of defense termed adaptive immunity, 
which is both highly specific for the pathogenic organism and which displays long­
term memory. The protein, carbohydrate and lipid components of foreign 
pathogens or tumours which provoke an immune response are known as antigens.
The immune system consists of specialized cells. All blood cells including those of 
the immune system derive from haematopoetic stem cells present in the bone 
marrow. These cells are termed pluripotent because they have the potential to 
differentiate into each diverse cell type which comprises blood. Pluripotent stem 
cells initially commit themselves to one of two cell lineages: myeloid stem cells 
which give rise to leucocytes (white blood cells), erythrocytes (red blood cells) and 
megakaryocytes (platelet precursor cells) or lymphoid stem cells which give rise to 
T and B lymphocytes (also known as T and B cells) as well as natural killer (NK) 
cells. Leucocytes comprise three polymorphonuclear cell types (neutrophils, 
eosinophils and basophils) as well as monocytes (mononuclear cells) and dendritic 
cells. Neutrophils engulf and destroy bacteria and fungi in a process termed 
phagocytosis; eosinophils assist in the killing of parasites while the natural function 
of basophils remains largely unknown. Monocytes in circulating blood are attracted 
to sites of inflammation within tissue (where they are termed macrophages or 
histiocytes) in order to capture antigens by phagocytosis and process them for 
delivery to T-lymphocytes. Similarly, bone-marrow derived dendritic cells (known 
simply as dendritic cells) act principally to process and display antigen and are 
critical for the activation of naive or unprimed T-ceUs.
B-lymphocytes are also able to process antigen for presentation to T-cells but in 
addition, they have the important capacity to differentiate further into plasma cells 
whose principal purpose is to secrete soluble protein receptors known as antibodies 
or immunoglobulin. Antibodies, which posses an almost limitless array of three­
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dimensional receptor conformations, are capable of binding to soluble antigen thus 
targeting it for clearance by leucocytes or macrophages. In addition, some 
antibodies act by occupying antigen sites critical for host cell entry; these are known 
as neutralizing antibodies. The arm of the immune system mediated by antibodies is 
known as humoral immunity. In contrast, T-lymphocytes, utilize membrane-bound 
T cell receptors (TCR) to recognize antigen and rather than attaching to soluble 
antigen, TCR recognize and bind to small fragments of antigen that are bound to 
major histocompatibility complex (MHC) Class I or II molecules present on the 
surfaces of intracellularly infected cells or antigen presenting cells. T-lymphocytes 
may be divided into two broad groups: helper T-cells (Th) whose main function is to 
secrete soluble signalling proteins known as cytokines and cytotoxic T-cells (CTL) 
which act to kill infected or transformed cells. The defensive processes mediated by 
T-cells are termed cellular or cell-mediated immunity.
NK cells are a subset of cytotoxic lymphocytes which do not express a TCR. They 
were first proposed to recognize cells which do not express MHC Class I molecules 
on their cell surface by Karre et al (Karre, et al. 1986). The receptor which mediates 
the recognition and cytotoxicity by NK cells has not been identified. However, the 
inhibition of NK cell mediated target lysis has been shown to be mediated by the 
interaction of MHC Class I and Class I-like molecules with inhibitory receptors on 
NK cells (Colonna 1997, Colonna and Samaridis 1995, Wagtmann, et al. 1995, 
Braud et al, 1998).
Cells of the immune system originate, mature and interact in specialized organs. 
Although all the cells of the immune system are derived from the bone marrow, 
interaction in other lymphoid organs is sometimes required for their optimal 
function. In particular, T-lymphocytes require passage through the thymus in order 
to mature fully and become capable of responding effectively to antigen. The bone 
marrow and the thymus, both sites of lymphocyte development and maturation, are 
known as central lymphoid organs. In contrast, lymph nodes are peripheral 
lymphoid organs which allow for the continuous physical interaction of T-cells, B-
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cells and antigen during natural infection and are critical for the optimal generation 
of both humoral and cellular immune responses. Mature lymphocytes enter the 
cortex (outer layer) of lymph nodes via a number of afferent lymphatic vessels and 
exit the medulla (inner layer) via a single efferent vessel. The cortex consists 
primarily of resting B-cells interspersed with dense follicles known as germinal 
centres which contain proliferating B-cells and follicular dendritic cells (FDC). 
Follicular dendritic cells, not to be confused with bone-marrow derived dendritic 
cells, retain antibody-antigen complexes on their cell surfaces and are critical in 
positively selecting B-cells displaying high-affinity immunoglobulin receptors, a 
process termed affinity maturation. The paracortical region between the cortex and 
the medulla is an area where helper T-cells contact antigen presenting cells (APC) 
such as macrophages and dendritic cells while the medulla is populated primarily by 
macrophages and plasma cells.
Other peripheral lymphoid organs include the spleen which appears to function 
primarily to dispose of damaged or aged erythrocytes. Gross and microscopic 
examination of the spleen, reveals large areas of red cells known as the red pulp, 
within which are tighter areas of tissue known as white pulp. White pulp is 
composed of T-cells circumscribed by B-cells suggesting that at this anatomical site, 
B-cells also present antigen to T-cells and conversely, T-cells may signal B-cells. 
Other accessory lymphoid organs such as gut-associated lymphoid tissue (GALT), 
bronchial-associated lymphoid tissue (BALT), mucosal-associated lymphoid tissue 
(MALT), tonsils, adenoids, appendix and Beyer's patches have slightly less organized 
histological anatomy than lymph nodes but subserve similar functions. All peripheral 
lymphoid organs serve as meeting places for lymphocytes and antigen presenting 
cells.
T-lymphocytes are defined by the expression of a clonal surface T-cell receptor. As 
discussed above, all T cells are defined by their expression of a clonal TCR. The 
TCR is a transembrane glycoprotein composed of either a  and (3 (Hedrick, et al 
1984, Yanagi, et al. 1984) or y and 8 (reviewed in Chien, et al. 1996) heterodimeric
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chains. (This thesis deals entirely with T lymphocytes bearing a(3 TCRs.) The 
extracellular domain of each chain contains a highly polymorphic and exposed face 
comprising the complementary determining regions 1, 2 and 3 (CDR 1,2 and 3) 
which allow for the recognition of a vast number of antigenic structures. The 
nucleotide and amino acid sequences of CDR 1 and 2 are less polymorphic than 
CDR3 and the crystal structure of MHC-peptide-TCR complex confirms that they 
bind to the less polymorphic regions of the MHC molecule, while the highly 
polymorphic CD3 region binds to the centre of the peptide-binding site of Class I 
molecules (Garboczi, et al. 1996, Garcia, et al. 1996). The cytoplasmic domain of the 
TCR associates with a multimeric signalling complex, CD3, itself consisting of 
several protein chains of which the Ç-chain is particularly important. The Ç-chain 
contains tyrosine-phosphorylation sites which are critical in transducing the TCR 
signal. Upon binding of the TCR by MHC-peptide, the phosphorylated Ç-chains are 
able to bind and activate a 70 kD cytosolic tyrosine kinase called zeta-associated 
protein (ZAP-70) (Chan, et al. 1992). and initiate a downstream signalling cascade 
resulting ultimately in activating the effector functions of the lymphocyte.
Two additional cell surface glycoproteins, the CD4 and CDS differentiation markers, 
define the two (helper and killer) subsets of T-lymphocytes. As mentioned, 
CD4+CD8- T-cells (helper T-cells) recognize antigen which is bound to MHC class 
II molecules on the surface of professional APC. Activation of helper cells results in 
the secretion of cytokines which bind to their counter-receptors on the surface of 
neighbouring cells, stimulating them to carry out effector functions. Thus cytokines 
act as local area hormones. Depending on the type of cytokines secreted, CD4+ 
cells may be termed Type 1 (Thl), Type 2 (Th2) or Type 0 (ThO). Thl cells 
predominantly secrete LL-2 and gamma-interfcron in response to IL-12 and 
preferentially stimulate a cellular response to infection while Th2 cells primarily 
secrete IL-4,5,10 preferentially tilting the immune response towards antibody 
production (reviewed in (Mosmanh and Sad 1996)). ThO cells secrete neither or a 
mixture of both types of cytokines. It should be noted that in humans, there is not 
as clear a distinction between Thl and Th2 responses as in mice.
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Maturation of T-lymphocytes occurs in the thymus. Immature T-lymphocytes from 
the bone-marrow migrate to the thymus (in which they are known as thymocytes) 
where they evolve to acquire a mature CD3+CD4+ or CD3+CD8+ phenotype. 
Generation of the TCR is a complex process involving the germline recombination 
of different gene segments. Each a  or p chain of the TCR is encoded by gene 
segments which consist of a V (variable), a J (joining) and a C (constant) region. In 
addition, P chains have a D (diversity) segment. The TCR P-chain genes rearrange 
first in CD4-CD8- immature thymocytes (double negative thymocytes). Expression 
of Rag-1 and Rag-2, genes which mediate germline rearrangement, produces first a 
D-J rearrangement, followed by a VDJ and finally a VDJC encoded chain. 
Expression of the p-chain on the immature lymphocyte surface in complex with a 
surrogate, pre-a chain and a CD3 complex signals the thymocyte to express CD4 
and CD8 genes and begin a-chain rearrangement. The a-chain rearrangement 
proceeds until an a-chain capable of efficient pairing with a P-chain is produced. At 
this stage the cells exhibit a CD3+CD4+CD8+ phenotype and are known as double 
positive thymocytes and are ready for negative and positive selection. Negative 
selection refers to the selective death of potentially autoreactive T-cells whose TCR 
recognize, with sufficient affinity, self-antigen in complex with self MHC molecule. 
This process is mediated by bone marrow derived dendritic cells which express 
MHC Class I and Class II molecules in complex with self-peptide. When the 
dendritic cells encounter double-positive thymocytes in the thymus, those T-cells 
whose TCR binds to MHC self-antigen with a high affinity are triggered to undergo 
programmed cell death via a physiological mechanism termed apoptosis. T-cells 
which survive negative-selection may then be positively selected by exposure to self 
MHC molecules expressed on cortical thymic epithelial cells. If the TCR is able to 
recognize MHC-self peptide with low affinity and the selecting molecule is Class H 
then CD3+CD4+ cells are selected; if the selecting molecule is Class I, CD3+CD8+ 
cells are positively selected. These mature, single-positive thymocytes are then ready 
to leave the thymus and enter the peripheral circulation as naive lymphocytes.
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Double-positive cells whose TCR cannot bind any self MHC molecules are neither 
positively nor negatively selected and die by apoptosis in the thymus. The entire 
family of mature T-cells which leaves the thymus is known as the T-cell repertoire.
Lymphocyte recognition of antigen. The adaptive immune response begins when 
lymphocytes expressing clonal T-cell receptors (TCR) bind to either MHC class I or 
class II molecules bearing antigenic peptide. CD4+ lymphocytes bind only to Class H 
complexes while CD8+ lymphocytes bind only to Class I complex. In addition, 
lymphocytes generally recognize only self-MHC in a phenomenon now termed 
MHC restriction. (Zinkemagel and Doherty 1974, Zinkemagel and Doherty 1975, 
McMichael, et al. 1977). In the case of CTL, TCR recognition of Class I complex 
initiates a series of intracellular events beginning with recruitment of Zap-70 and 
ending with the destruction of the peptide-bearing target cell. The initial 
demonstration of MHC Class restriction was followed by experiments showing that 
CTL recognize fragments of antigenic protein in complex with Class I molecules on 
the surface of virus infected cells (Townsend and Bodmer 1989, Townsend, et aL
1986). These data were ultimately confirmed by X ray crystallographic studies of 
several human and murine class I molecules (Bjorkman, et al. 1987).
MHC Class I molecules consist of a 45kD polymorphic transmembrane heavy chain 
and a smaller 12kD non-polymorphic chain, beta-2 microglobulin (|$-2M). The 
heavy chain comprises three domains, <xl, oc2 and oc3. The ocl and a2 domains 
form a beta-sheet platform upon which rests diagonally two highly polymorphic 
alpha helices, together forming the floor and sides of the peptide-binding groove 
(Figure 1). The ends of this groove in Class I molecules are closed and provide 
hydrogen-bonding sites for the N and C-terminal domains of the peptide thus 
burying the peptide at both ends and limiting the size of most Class I peptides to 8- 
10 amino acids (Madden, et al, 1993; Saper, et al, 1989). Longer peptides binding in 
the groove may do so by bulging the central portion of the peptide outwards or in 
exceptional cases the N or C-terminal domains may extend from the outside pockets 
as they do in MHC Class II complexes. Numerous hydrogen bonds may be formed
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between the peptide and the heavy chain along the length of the groove, accounting 
for the broad diversity of peptides capable of binding to given alleles of class I 
molecules. Specific peptide binding sites or pockets vary from allele to allele, 
preferentially binding particular amino acids which are thus termed anchor residues. 
Similarly, certain amino acids of the peptide point their side chains out of the groove 
where they are free to interact with the T-cell receptor.
15
Figure 1: Crystal structure of HLA-A2
The structure of the MHC Class I molecule, HLA-A201 complexed with a peptide 
epitope from HIV Pol (TLKEPVHGV) displayed in ribbon (top) and spacefill 
(bottom) formats viewed from two directions. The peptide binding groove (green), 
formed by the a  1 and a2 helical domains of the heavy chain holds the nonameric 
peptide (red).
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Figure 1: Structure of HLA A*0201
Antigen-presenting cells process and display antigen for helper T-cells.
All nucleated cells normally express surface MHC Class I molecules and thus may 
be recognized by CTL when infected by intracellular pathogens. Class U MHC 
expression however is limited to a subset of specialized cells termed antigen- 
presenting cells (APC). APC include macrophages, B lymphocytes and dendritic 
cells and generally, only these cells may be recognized by CD4+ helper T cells. In 
addition to MHC Class II molecules, APC often express co-receptors, which upon 
binding their counter-receptor on CD4 cells, provide a "second signal" which 
appears to be necessary for optimal CD4 T-cell activation. The requirement for a 
second signal presumably adds an additional layer of safety to the immune response 
and thus may play a critical role in preventing autoimmune responses. Self antigens 
which are recognized by lymphocytes expressing aberrant TCP's (which have 
escaped negative selection) may still be rendered anergic (that is, made incapable of 
responding to antigen) if they are activated in the absence of a proper second signal. 
A number of accessory or adhesion molecules expressed on APC's may deliver a 
second signal and also increase the avidity and affinity of the lymphocyte-APC 
interaction but the most important of these appear to be CD80/86 (B7) which binds 
to CD28 expressed on T-cells. However, mice deficient in CD28 are still capable of 
mounting seemingly normal lymphocyte responses suggesting that alternative 
pathways exist (Shahinian, et al. 1993). Bone-marrow derived dendritic cells (DC) 
appear to be particularly potent APC probably because of their high expression of 
both MHC Class II and CD80 molecules (Tan, et al. 1992) and are the principal 
activators of naive T cells.
Antigenic intracellular proteins are degraded into small fragments in the cytosol. As 
mentioned previously, protein antigens are not presented in whole by MHC 
molecules but rather are degraded into short peptides before association with class I 
or class II molecules (Townsend and Bodmer 1989); (Germain 1991). This process 
begins in the cytosol where translated viral and bacterial proteins as well as tumour 
derived proteins are tagged with ubiquitin and targeted for degradation by a 
proteasome complex consisting of two subunits, LMP2 and LMP7 (Goldberg and
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Rock 1992). Proteasomal products, typically oligopeptides 3-15 amino acids in 
length are actively translocated from the cytosol into the endoplasmic reticulum 
(ER) by a membrane bound transporter-associated with antigen processing protein 
(TAP), itself composed of two subunits, TAPI and TAP2 (Trowsdale, et al. 1990). 
Peptide fragments associate with newly synthesized class 1 heavy chains in the ER 
and are stabilized by association with beta-2 microglobulin before trafficking to the 
Golgi apparatus and then to the cell surface. In comparison, MHC Class H-associated 
peptides are normally derived from extracellular proteins taken into professional 
APC by phagocytosis or endocytosis and digested in lysosomes by enzymes known 
as cathepsins. These peptide fragments, generally longer than those on Class I 
molecules, are bound to MHC Class H molecules in special endosomal 
compartments before export of the complexes to the cell surface (reviewed in 
Germain 1991). This apparent compartmentalizadon of MHC Class I and II antigen 
processing is not absolute and endocytosed extracellular antigen can sometimes be 
shunted to the Class I processing pathway (Rock, 1996).
Effector functions of CTL.
When the TCR which are present on CTL recognize and engage MHC Class I- 
peptide complexes, a series of intracellular signalling events are initiated culminating 
in the destruction of the antigen-bearing cell. This occurs through two distinct 
mechanisms (Figure 2). The main pathway of cytotoxicity is explained by the 
granule exocytosis model (Henkart 1994, Podack, et al. 1991) and involves the 
secretion of soluble, pore-forming proteins, perforin as well as the serine proteases, 
such as granzymes. Expression of perforin is generally confined to CTL, NK cells 
and yô T-cells. Upon CTL activation, preformed cytoplasmic granules containing 
perforin subunits are released into the extracellular compartment where Ca++ 
dependent conformational changes allow perforin monomers to integrate and 
polymerize in the target cell membrane. These pores allow for the entry of 
granzymes which initiate an apoptosis signalling cascade. Perforin cytotoxicity, 
however, cannot be the sole mechanism of CTL directed lysis since perforin- 
deficient mice are also able to lyse lymphoid cells (albeit with a reduced efficiency)
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(Kagi, et al. 1995, Rouvier, et al. 1993, Walsh, et al. 1994). The second pathway of 
CTL induced death was found to involve the interaction of Fas on target cells with 
its ligand FasL on CTL.
Fas (CD95), a member of the tumour necrosis factor receptor family, surface 
molecule containing a cytoplasmic death domain. Binding of Fas either by antibody 
or by its natural ligand, FasL results in the initiation of apoptosis. Cells such as 
primary fibroblasts do not express Fas and hence when used as target cells rely 
entirely on the perforin pathway for cytotoxicity. Lymphoid cells however, express 
Fas accounting for their susceptibility in perforin-deficient mice. When perforin- 
deficient mice were crossed with Ipr mice, which bear a natural Fas mutation, no 
CTL activity could be detected even on lymphoid cells demonstrating that these two 
pathways account for all of the cytoxicity of CD8+ cells. Both perforin-dependent 
and Fas-dependent death are the result of apoptosis of the target cell. However, 
caspase-inhibitors which block the signalling cascade necessary for apoptosis of the 
target cell do not prevent its death by lysis (Sarin, et al. 1997). Thus, perforin alone 
may lyse target cells but granzymes and Fas are necessary for apoptosis. Aside from 
directly killing target cells, activated CTL also release tumour necrosis factor alpha 
(TNFcc), which potentiates killing, and gamma interferon (fFN-y) which renders 
neighbouring cells more resistant to viral infection. The CTL which initially expand 
on antigen contact can persist as memory cells. Recently, Wagner et al have 
reported that two anti-viral chemokines, macrophage inflammatory protein (MIP)- 
loc and RANTES may also be released with granzymes by CTL (Wagner et al).
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Figure 2: CTL recognition and effector function.
The clonal ocp T-cell receptor (TCR) on a cytotoxic T lymphocyte (CTL) recognizes 
antigenic peptide (P) in association with an MHC Class I molecule (HC= heavy 
chain, p2m - beta 2 microglobulin). Upon recognition, the CTL is triggered to 
release perforin (Perf) and granzymes (Gran). In the presence of Ca++, perforin 
polymerizes in the target cell to form pores which allow entry of proteolytic 
granzymes which trigger a signal cascade (dotted arrow) resulting in apoptosis of 
the target cell. Activated CTL also express Fas ligand (FasL) and can trigger Fas- 
dependent apoptosis in cells expressing Fas.
20
Figure 2: CTL recognize and kill target cells via two pathways
Ctt++
CTL act to limit virus replication.
MHC class I restricted CTL were first shown to play a critical role in regulating 
virus inflections in mice infected with lymphocytic choriomeningitis virus 
(Zinkemagel and Doherty 1974, Zinkemagel and Doherty 1975) although in this 
infection they act to mediate the immunopathology of the disease (Buchmeier, et al. 
1980). CTL were subsequently detected in murine influenza vims infection 
(Zweerink, et al. 1977), and it was demonstrated that the adoptive transfer of CTL 
clones produced potent anti-viral effects (Braciale, et al. 1981, Lin and Askonas 
1981, Lukacher, et al. 1984). Similar observations were made for respiratory 
syncytial vims (RSV) (Cannon, et al. 1988) and herpes simplex infection in mice 
(Bonneau and Jennings 1990).
CTL have been detected in many human vims infections (Bangham and McMichael 
1989), although evidence for a protective role in these infections has been harder to 
obtain. In influenza, CTL levels correlated with protection from deliberate infection 
of volunteers (McMichael, et al. 1983) and in immunosuppressed patients following 
bone marrow transplantation (BMT), CTL levels correlate with protection from 
cytomegalovirus (CMV) infection (Reusser, et al. 1991). In addition, the transfer of 
CMV-specific CTL appears to protect BMT patients from CMV disease (Walter, et 
al. 1995).
Adoptive transfer of T-cells has also been shown to induce regression of post­
transplantation lymphoproliferative disorders (PTLD), almost all of which are 
associated with Epstein-Barr vims (EBV). Following acute EBV infection, the vims 
persists latently in some B cells switching its gene expression pattern such that that 
only the nuclear antigen, EBNA-1 (Rowe, et al. 1987, Young, et al. 1989) is 
translated. Thus the latent vims escapes CTL detection because EBNA-1 is normally 
not processed in the MHC Class I pathway. Changes in the viral gene expression 
program involving the breakthrough synthesis of non-EBNA-1 proteins and 
transformation of lymphoid cells is controlled by a strong lifelong memory CTL 
response. However loss of CTL function by immunosuppression allows for the
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development of PTLD (Beral, et al. 1991, Rowe, et al. 1991). The role of CTL in 
preventing uncontrolled EBV-driven lymphoproliferation has been strongly 
supported by recent reports that it is possible to treat some EBV-related lymphomas 
by the transfer of donor derived leucocytes or EBV-specific CTL (Papadopoulos, et 
al. 1994, Rooney, et al. 1995).
Persistent viruses have strategies to escape recognition by CTL. The importance of 
CTL in the control of viral infections is also underscored by the findings that nearly 
all persistent viruses studied to date, including most of the human herpesvirus 
family, possess mechanisms for escaping CTL detection and destruction. For 
example. Herpes simplex virus produces a protein ICP-47 which binds TAP 
preventing translocation of peptides to the ER (Fruh, et al. 1995, Hill, et al. 1995, 
York, et al. 1994). Human cytomegalovirus (CMV) expresses at least five protein 
products which help the virus evade CTL. US2 and US 11 each shunt newly 
synthesized Class I molecules from the ER to the cytosol where they are degraded 
(Wiertz, et al. 1996, Wiertz, et al. 1996). Despite homology to US2 another CMV 
early gene product US 3 does not degrade Class I complexes but retains them in the 
ER (Ahn, et al. 1996, Jones, et al. 1996). Two other gene products UL18 and m l44 
are class I homologs and can engage NK inhibitory receptors preventing NK cell 
lysis. Most recently, Gilbert et al have shown that the CMV viral matrix protein 
pp65 has Ser/Thr kinas activity and phosphorylation of the principal immediate 
early protein, p72 prevents its recognition by CTL (Gilbert, et al. 1996). Finally, as 
mentioned, EBNA1 of EBV also avoids antigen presentation, probably by blocking 
its proteasomal degradation (Levitskaya, et al. 1995). There is also some evidence 
that HTV accessory proteins may enable evasion of the immune response as both 
Vpu and Nef appear to downregulate expression of MHC Class I molecules in HIV 
infected cells (Kerkau, et al. 1989, Collins, et al. 1998).
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The Cellular Immune Response to HTV
The biology of HTV
HIV-1 is a lentivirus and a member of the family Retroviridae. The general structure 
of the virus is presented in Figure 3. Its genome is encoded in two identical sense- 
strands of RNA and the virus is closely related to both HIV-2 and simian 
immunodeficiency virus (SIV). The sequence of cell infection and replication has 
been partly established. The envelope glycoprotein complex consisting of the GP120 
and GP41 binds to the CD4 glycoprotein on helper T-cells (Maddon, et al. 1986, 
McDougal, et al. 1986). Subsequent binding of the chemokine receptor CCR5 (or in 
some cases, an alternate chemokine receptor) results in virus/target membrane 
fusion and cell entry. Different isolates of HTV use different co-receptors for cell- 
entry, and co-receptor usage is the principal basis for cellular tropism. HTV-QIB and 
other T-cell-tropic strains of HTV-1 use the C-X-C-chemokine receptor CXCR4 
(LESTR/fusin) (Feng, et al. 1996), the ligand for which, SDF-1, has recently been 
identified and blocks entry of T-tropic HIV isolates (Bleui, et al. 1996, Oberlin, et al. 
1996). Macrophage-tropic isolates predominantly use CCR-5, a CC-chemokine- 
receptor which binds RANTES, MIP-lcc and MIP-16 (Alkhatib, et al. 1996, Deng, 
et al. 1996, Dragic, et al. 1996) which block entry of these isolates. In some cases, 
HTV strains may use other members of the CC-chemokine-receptor family, 
principally CCR-3 (Choe, et al. 1996) and CCR2b (Doranz, et al. 1996).The crystal 
structure of HTV GP-41 suggests structural similarity to the influenza HA protein 
which plays a critical role in influenza viral fusion (Carr, et al. 1997). After entry the 
viral capsid is partially uncoated exposing an RNA-protein complex capable of 
reverse transcription. Reverse transcription is inefficient in quiescent cells suggesting 
the need for host components in this process (Zack, et al. 1990). Reverse 
transcription produces a linear double-stranded DMA, the Gag matrix protein, the 
accessory Vpr protein and the viral integrase (Heinzinger, 1994). The protein 
components are all derived from the infecting virus and no new protein synthesis is 
required. The pre-integration complex is transported to the nucleus where integrase 
catalyses the exonuclease trimming of DS-DNA, endonuclease cleavage of host
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chromosomal DNA and ligation of free viral and host chromosomal DNA (Katz and 
Skalka 1994). The latent integrated DNA is known as the pro virus. A number of 
viral, cellular and exogenous stimuli can activate transcription of the provirus from 
latency. The viral transactivator Tat can stimulate virus expression (Gaynor 1995); 
moreover, transcription can be initiated by mitogens, DNA damage as well as by 
transactivators from other co-infecting viruses (Stein, et al. 1989, Walker, et al. 
1992, Zack, et al. 1988). The full length 9 Kb HTV transcript may then be used as 
substrate for splicing reactions giving rise to smaller spliced viral RNAs (Schwartz, 
et al. 1990) or it may be transported to the cytoplasm to serve as a template for 
synthesis of further Gag and Gag-Pol products. The process of virus assembly at the 
cell surface is enhanced by the Vpu protein (Jabbar 1995). The components of the 
virus particle, Gag and Gag-Pol, processed envelope proteins, viral RNA and Vpr 
protein interact at the cell surface and bud from the cell to form an immature 
noninfectious virus particle. Maturation of the free virus particle is mediated by the 
viral protease, resulting in proteolytic processing of the Gag and Gag-Pol precursor 
proteins and infectious virus particles (Craven, et al. 1991).
24
Figure 3: Structure of HIV
The major structural and functional elements of the HTV virion include the envelope 
(Env) glycoproteins gp41 and gpl20, the Gag matrix proteins, p l7  and p24, reverse 
transcriptase (RT), integrase, protease, and two strands of single-stranded RNA (SS 
RNA). The gpl20 glycoprotein is the viral receptor for human CD4 while gp41 
assists in viral penetration of host cells.
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Figure 3: HIV Virion Structure
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The role of HIV-specific CTL in the natural history of HIV infection.
There is considerable evidence that CTL play an important role in the control of 
HTV infection by direct effects on viral replication. This was first shown by culturing 
HTV from mononuclear cells derived from healthy seropositive subjects following 
the depletion of the CD8+ cells fraction and then suppressing virus production in a 
dose-dependent manner by restoring the depleted cells (Walker, et al. 1986). Further 
studies demonstrated that this anti-HIV activity is correlated with the patient's 
clinical state and in particular, with the CD4+ cell count of the infected individual 
(Mackewicz, et al. 1991). Particularly vigorous CTL activity has been described in a 
group of long-term non-progressors (Cao, et al. 1995), suggesting that this may be 
one of the more important mechanisms controlling the length of the asymptomatic 
period in HTV infection.
Although immunological abnormalities, particularly of CD4+ cell function, may be 
detected even in the earliest stages of HTV infection, there is nevertheless a vigorous 
immune response to the virus. Antibodies are generated against all the structural 
and nonstructural gene products, some of which neutralise heterologous isolates of 
HTV and others which can initiate antibody-dependent cellular cytotoxicity in vitro. 
A vigorous CTL response against HTV is also observed. The detection of HIV- 
specific CTL was first described in 1987 and was remarkable in that HLA-restricted 
CTL specific for both Gag and Env gene products could be readily detected by 
placing freshly separated peripheral blood mononuclear cells (Walker, et al. 1987) or 
in alveolar lymphocytes from patients with HIV-related pneumonitis (Plata, et al.
1987) into Cr-release assays, without any need for prior in vitro culture or 
restimulation. This level of CTL activity was previously undescribed for other virus 
infections and has only been detected since in infection with HTLV-1, another 
retroviral infection (Jacobson, et al. 1990, Parker, et al. 1992). Subsequent studies 
have estimated that between 15% and 88% of HIV-infected subjects have “fresh” 
or primary HIV-specific CTL (Grant, et al. 1992, Koup, et al. 1989, Riviere, et al. 
1989, Walker, et al. 1987). The large range of detection may depend on the different 
assay conditions used in different labs.
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MHC Class I restricted CTL have been demonstrated against most of the HTV gene 
products, principally Gag, Pol and Env, but also against the accessory proteins such 
as Nef, Tat and Vif (McMichael and Walker 1994). CTL have usually been obtained 
from peripheral blood, but they have also been isolated from infected organs, such 
as lungs (Plata, et al. 1987), lymph nodes (Hadida, et al. 1995, Langlade-Demoyen, 
et al. 1988), spleen (Cheynier, et al. 1994), central nervous system (CNS) (Jassoy, et 
al. 1992, Kalams and Walker 1995) and from the vaginal mucosa of SlV-infected 
macaques (Lohman, et al. 1995). Although most of the descriptions of HIV-specific 
CTL have been in adults, it is clear that perinatally-infected children can also mount 
an HIV-specific CTL response, even in the first year of fife (Luzuriaga, et al. 1995).
The first identified peptide epitope was an HLA-B27-restricted 15-mer in Gag 
(Nixon, et al. 1988), now known to be the decamer KRWDLGLNK (Rowland-Jones 
and McMichael 1993). Many peptide epitopes have subsequently been reported 
(reviewed in McMichael and Walker 1994).
A striking feature of the cellular immune response to HTV is that the HIV-specific 
CTL of an infected person are directed towards multiple epitopes. This differs from 
previously described human and murine virus infections where a dominant CTL 
response has usually been identified for a given MHC allele. For instance, H-2b mice 
focus their entire CTL response to vesicular stomatitis virus (VSV) on a nine amino 
acid stretch of the nucleocapsid protein (Van Bleek and Nathenson 1990). People 
infected with HTV, in the mid-phase of their infection, usually make CTL responses 
against multiple epitopes through one or several of their HLA molecules, even 
though one may be the dominant response. For example, at least three peptides 
from Gag are restricted by HLA-B8, and CTL against all three epitopes can be 
detected in a single donor (Phillips, et al. 1991) and one of these donors also makes 
a strong CTL response to an A2-restricted peptide in reverse transcriptase 
(McAdam, et al. 1995, Moss, et al. 1995). Another healthy donor has been found to 
make CTL responses to at least six different peptides from an assortment of HIV
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proteins (Harrer, et al. 1996). There are exceptions including an HIV-infected 
haemophiliac whose entire CTL response has been directed towards a single epitope 
in Gag over several years (Goulder, et al. 1997, Nixon, et al. 1988). In addition, 
careful study of an identical twin pair who were infected at the same time with the 
same strain of HTV, showed dissimilar patterns of epitope recognition suggesting 
that random viral mutations play a role in directing the CTL response (Goulder, et 
al, 1997).
Suppression of HTV replication can can also occur across a semi-permeable 
membrane or by the transfer of supernatant from CD8+ cells, suggesting that CTL 
release soluble factors (CD8+ anti-viral factor or CAP) which play a role in the 
suppression of HTV. However, there is little consensus as to whether CAP is 
primarily a property of MHC Class I-restricted CTL since potent suppression has 
been observed without any HLA matching (Brinchmann, et al. 1990, Levy, et al. 
1996, Toso, et al. 1995). However, in other studies MHC Class I matching provides 
maximal antiviral activity and the cells which mediate the suppression have the 
typical phenotype of CTL (Tsubota, et al. 1989). Detailed analysis of a panel of 
CD8+ clones from asymptomatic HIV-infected donors showed that the majority of 
suppressing clones did not exhibit HIV-specific cytoloytic activity, and that some 
specific CTL clones showed no evidence of viral suppression - although a few clones 
had both properties (Toso, et al. 1995). HTV-suppressing CD8+ cells have been 
shown to express certain cell-surface markers: DR+, C D llb- (Toso, et al. 1995), 
CD28+ (Landay, et al. 1993), CD29+, CD45RA-, LFA-1+ (Tsubota, et al. 1989), 
CD45RO+ and CD38+, but a diversity of other markers has been observed among 
suppressing clones, suggesting that CD8+ clones with anti-viral activity are 
phenotypically heterogeneous (Toso, et al. 1995).
The CC-chemokines MIP-lcc, M IP-lp and RANTES (Cocchi, et al. 1995) produced 
by CD8+ T-cells are potent suppressive factors presumably because they bind to 
their receptor CCR-5 thus preventing HTV co-receptor usage. These chemokines 
appear to be produced in an antigen-specific manner (Yang, et al. 1996, Yang, et al.
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1997) and their secretion is responsive to increasing antigen exposure (Price, et al.
1998). In addition, IL-16 has some suppressive activity when produced by CD8+ 
cells from SlV-infected African green monkeys, but with much lower potency than 
the CC-chemokines (Baier, et al. 1995). The HTV-suppressive activity of human IL- 
16 has been questioned (Mackewicz, et al. 1996), and it likely that chemokines 
described to date do not account for all of the CAP activity (Levy, et al. 1996). 
Furthermore, additional chemokines are being identified in this rapidly progressing 
field. For instance, macrophage derived chemokine (MDC) has been isolated from 
the culture supernatant of an immortalized CD8+ clone and shown to possess 
suppressive activity against both laboratory and wildtype HIV strains (Pal, et al. 
1998).
Initial observations showed that the activity of the CC-chemokines is greatest against 
macrophage-tropic and primary HTV isolates, and they have little effect against 
laboratory-adapted strains such as HTV-IIIB/LAI (Cocchi, et al. 1995). These 
observations were subsequently explained by the identification of members of the 
chemokine receptor family as co-receptors for HTV. These findings account for 
CD8+ T-cell-mediated HTV-suppression by the CC-chemokines, and explain why 
there has not always been consistency between past studies of HTV suppression 
using strains of HTV which differ in their tropism and presumably also their co­
receptor usage.
The relative contribution of CTL-mediated killing and the antiviral effect of 
chemokines and other factors produced by CD8+ cells to control of HTV infection 
has yet to be determined. Antiviral factors do not affect the life-span of infected 
cells; if there was no T-cell-mediated cytolysis and the virus was cytopathic with a 
11/2 of 2 days, the measured half-lives of infected cells would be as described (Ho, et 
al. 1995, Wei, et al. 1995). If the only antiviral activity of CD8+ T cells was antigen- 
stimulated chemokine production, viral escape by mutation of CTL epitopes (as 
described below) would probably be unlikely because mutant and wild-type virus 
released from adjacent cells would be equally susceptible to the chemokines
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although it is possible that mutant virus might stimulate the release of chemokines 
less effectively so there could be weaker responses in the environment of mutant 
virions. The increasing evidence for viral escape from CTL implies that lysis is 
important in control of HIV but at the cost of killing CD4+ T cells and 
macrophages.
This conundrum may yet prove to be important in the pathogenesis of AIDS. Lysis 
of CD4+ cells results in poorly functional CTL. Poorly functional CTL result in less 
CD4+ cell lysis and higher viral loads. Ultimately, the balance of infected and 
uninfected CD4+ cells and the functionality of infected CD4+ cells may determine 
the extent of host disease. In a situation where a small minority of CD4 cells are 
infected with HTV, destruction of these cells is beneficial to the host. However, in 
advanced AIDS where a large proportion of CD4+ cells are infected, loss of 
remaining cells through CTL lysis may severely compromise host defense (assuming 
these cells can still release IL-2 in an antigen specific manner).
MHC Class I restricted HTV epitopes
When the positions of the epitopes are mapped (for example, in Nef) it is apparent 
that there are clusters of epitopes in certain regions of the viral proteins (Culmann, 
et al. 1991). The reasons are unclear but may relate to proteasomal access to these 
regions of the virus. On the other hand, epitopes are more evenly distributed 
through Gag. There are several instances of the same epitope being presented by 
more than one class molecule - for example the Nef peptide 73-82 contains epitopes 
presented by HLA-A3, A ll and B35 (the latter is an octamer, 74-81, but the 
peptides presented by A3 and A ll are identical) (Culmann, et al. 1989, Koenig, et 
al. 1990); another Nef peptide, 190-198, is presented by three HLA-A2 subtypes as 
well as HLA-B52 (Hadida, et al. 1995). Although generally donors respond to the 
epitopes in a predictable manner, indicating the strong selective influence of the 
HLA type, there are examples where all donors with a particular class I molecule do 
not respond to the same epitope: for example, donors with HLA-A*201 usually 
respond either to an epitope in pl7 Gag or to one in Pol, but rarely to both
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(McMichael and Walker 1994). These epitopes are present in different amounts at 
the cell-surface of HIV-infected A2-expressing cells, with the pl7 peptide being 
more abundant (Tsomides, et al. 1994), but this does not explain why the Pol 
response is immunodominant for some donors. Responses to a third HLA-A2 
epitope, in a highly conserved active site region of reverse transcriptase have been 
rarely described (Harrer, et al. 1996). In a study of CTL responses to the Gag 
protein, HLA type alone did not always predict the target of the response (Buseyne, 
et al. 1994). It is possible that mutations in the flanking regions of CTL epitopes 
may lead to different rates of processing, or that immune response genes other than 
HLA may influence immunodominant responses, but these mechanisms have yet to 
be demonstrated in humans. These studies underline the extent and complexity of 
the CTL response to HTV.
Correlation between CTL activity and disease
The natural clinical history of AIDS may be correlated to a number of laboratory 
parameters (Figure 4) and much of the evidence for the role of HIV-specific CTL in 
controlling HTV infection has come from observations of CTL activity in HIV- 
infected people at different stages of disease. Although correlation of CTL activity 
and disease state provides strong circumstantial evidence of their importance, it 
remains to be fully proven that CTL are directly responsible for control of vims 
load, rather than simply a marker of immunological good health. These studies 
have also attempted to be quantitative, whereas qualitative differences in CTL 
activity (e.g. to epitopes which cannot vary without damaging the vims) may be 
more important. Direct evidence that CTL are important for controlling HIV 
infection requires unequivocal evidence that escape mutations are selected in vivo, 
demonstration that adoptive transfer of CTL reduces vims load and demonstration 
that vaccine induction of CTL alone can protect against infection with HTV (or SIV).
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Figure 4: Natural History of AIDS
Infection by HTV is followed at around 6 weeks by an acute viremia, manifested 
clinically as acute retroviral syndrome and associated with high plasma viral loads 
and a depressed CD4 cell count. HIV-specific CTL develop shortly thereafter 
followed by detectable antibody to Env glycoproteins. The viral load then decreases 
concomitant with a rise in the CD4 cell count and the patient is generally 
asymptomatic for years before a decline in both CD4 and CDS cells and a rise in 
viral load signal clinical demise.
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CTL response to acute HTV infection
CTL can be detected during early stages of acute HIV infection, even before the 
development of serum antibodies. The high levels of viraemia that characterise 
primary infection with HIV-1 and the accompanying vigorous anti-HIV immune 
response generally occur 3-6 weeks after HTV exposure, and are frequently 
accompanied by clinical symptoms of acute retroviral syndrome including include 
fever, malaise, rash and lymphadenopathy. At this time, plasma viral RNA levels 
may be as high as 10 million copies per ml (Mellors, et al. 1995, Piatak, et al. 1993), 
and the CD4 count is low - occasionally it may be sufficiently depressed to allow the 
development of opportunistic infections (Gupta 1993). CD4+ T cell function is also 
markedly abnormal (Pedersen, et al. 1990). There is usually a profound CD8+ T-cell 
lymphocytosis, with huge (up to 40% of all T cells) oligoclonal expansions which 
express CD38, CD27 and DR but are CD28 negative (Roos, et al. 1994). In culture 
these CD8+CD28- cells are primed for apoptosis (Brugnoni, et al. 1996), and 
probably represent terminally differentiated effector CTL (Pantaleo, et al. 1994). 
Over the next few weeks, the plasma virus load falls by several orders of magnitude, 
although antibodies with the capacity to neutralise the virus are rarely detected at 
this stage (Ariyoshi, et al. 1992, Koup, et al. 1994).
HTV-specific CTL precursors have been described as early as two days after clinical 
presentation, and within three weeks of the onset of symptoms in four out of five 
patients in one study (Koup, et al. 1994); these CTL had specificity for the Env, Gag 
and Pol proteins. In another study HIV-specific CTL were detected in four out of 
five patients as early as 6-8 days after the development of symptoms; CTL 
recognising Env, Gag and Tat were generated, although the predominant response 
appeared to be towards gpl60 (Borrow, et al 1994). Both of these studies described 
single donors who failed to make detectable CTL responses and who exhibited a 
rapidly progressive course of HTV infection with high levels of viremia, suggesting 
that the early generation of a vigorous HIV-specific CTL response may not only be 
responsible for the initial control of viremia but also influence the subsequent disease 
course. Another study examining the specificity of HIV-specific CTL responses in
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acute infection found that 7 out of 9 donors had detectable CTL activity in the first 
four weeks after seroconversion (Lamhamedi-Cherradi, et al. 1995).
Studies of the TCR repertoire in primary HTV infection have shown that the CD8+ 
response is represented by large but transient oligoclonal expansions in many 
patients (Pantaleo, et al. 1994). These expansions are marked by a large proportion 
of CD8+ cells bearing VB chains which have restricted amino acid sequences in the 
CDR3 (hypervariable) TCR region. Similar findings have been made in acute SIV 
infection (Chen, et al. 1995, Chen, et al. 1996). These large oligoclonal T cell 
expansions have also been described infectious mononucleosis and other acute viral 
infections (Callan, et al. 1996, Tripp, et al. 1995). In HIV infected patients, poor 
prognosis was associated with a particularly narrow repertoire of CD8+ expansions, 
and it was suggested that a relatively limited CD8+ response may facilitate viral 
escape from the immune system or lead to more rapid immune exhaustion 
(Pantaleo, et al. 1994, Safrit and Koup 1995). More detailed study of the fine 
specificity of the acute HIV-specific CTL responses of two patients mapped them to 
epitopes in gp41; clones from these patients recognised their autologous virus 
sequences and continued to do so for up to 15 weeks after presentation (Safrit, et aL 
1994). However, in two other patients with evidence of rapid progression, virus 
variants with changes in the epitopes recognised by their dominant acute CTL 
response, sufficient to abrogate CTL recognition, emerged during the first few 
months of infection (Borrow, et al. 1996, Price, et al. 1997). These last findings 
provide strong evidence for the importance of CTL in the control of the initial 
viremia.
In addition to cytolytic responses, CD8+-cell-mediated suppression of HIV 
replication has been described early in HTV infection, before the development of a 
neutralising antibody response (Mackewicz, et al. 1994). In these studies, CD8+ 
suppressive activity was most marked before seroconversion, and showed an 
inverse correlation with plasma viral load in three out of seven subjects. Further 
evidence to support this has come from the simian model of SFVmac infection.
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where CD8+ cells capable of inhibiting SIV replication were detected within 13-60 
days of experimental infection (Tsubota, et al. 1989). Finally, SIV infected macaques 
depleted of CD8+ cells early in infection by the use of and-CD8 monoclonal 
antibodies had prolonged and high viremias as compared to mock antibody-treated 
monkeys (Matano, et al. 1998). Taken together, these studies demonstrate that most 
people with acute HIV infection develop a broadly reactive HIV-specific CTL 
response soon after exposure, and that the resolution of acute viraemia is in parallel 
with both the cytotoxic and non-cytolytic CD8+ activity.
Maintenance of the CTL response
CTL are also present during the asymptomatic phase of HIV infection. As indicated 
above, in the asymptomatic mid-phase of HTV infection, as many asl% of peripheral 
blood mononuclear cells (PBMCs) can be effector CTL (Gotch, et al. 1990), while
estimates of memory CTL range from 1 in 10^ to 1 in 10^. The discrepancy 
between effector and memory CTL numbers is consistent with some degree of 
terminal differentiation of the effector CTL, possibly as a result of overstimulation: 
this could leave the CTL vulnerable to depletion from clonal exhaustion 
(Moskophidis, et al. 1993).
The vigorous CTL response against HTV is likely to result from continuous antigen 
stimulation by a virus that is constantly turning over in multiple sites (Ho, et aL 
1995, Wei, et al. 1995). However, CTL have also been detected in long-term non- 
progressors with low levels of plasma viraemia (Harrer, et al. 1996). It has been 
theorized by Nowak and Bangham that low antigen loads might stimulate strong 
CTL responses if helper T cell function is good and that the same level of CTL 
might require far more antigen when helper T cell functions (or other accessory 
factors) are impaired (Nowak and Bangham 1996).
Progression to AIDS
HTV disease progresses despite the presence of virus-specific CTL. There have been 
several attempts to correlate either the specificity or the magnitude of the HIV-
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specific CTL response with clinical outcome. Studies in the Amsterdam cohort of 
HIV-infected donors recruited since 1984 compared the Gag-specific CTL precursor 
(CTLp) frequency in long-term asymptomatic (LTA) donors and rapid progressors 
(Klein, et al. 1995). All of the LTA subjects had detectable CTLp against Gag, 
estimated at between 1/300 and 1/21,000, which were maintained over several years 
of follow-up, during which CD4+ cell numbers and function remained stable and 
virus load was low. In contrast, one of the six rapid progressors had no detectable 
Gag-specific CTL, and in four others it was either transient or declined to 
undetectable levels with disease progression. These studies demonstrated that long­
term asymptomatic HIV infection is characterized by sustained Gag-specific CTL 
responses, although the rapid progressors were not protected from disease despite 
initially high levels of circulating CTL.
Studies in a large cohort (MACS) of homosexual men in Pittsburgh examined the 
presence of “fresh” effector CTL (CTLe) in healthy HIV-infected subjects* and 
detected CTLe against at least one of Gag, Pol and Env in 83% of the men during 
the first 8 years after seroconversion (Rinaldo, et al. 1995). There was no correlation 
between the levels of CTLe activity and the CD4+ or CD8+ count, or the duration 
of infection or the use of antiretrovirals, nor did the presence or absence of CTLe 
predict the disease course. These findings contrast with those in a French study, 
where “fresh” effector Gag-specific CTL were elicited in 18 out of 38 patients. The 
risk of progression to CDC stage IV disease was estimated to be 1.89 in those 
without CTLe to Gag, compared with those with a detectable response (Riviere, et 
al. 1995). There was no significant difference in the risk of progression for those 
with or without CTLe towards Env. These studies may be adversely affected by the 
insensitivity of the current CTLe assay; detectable lysis at four hours needs a CTLe 
frequency of around 1%; lower levels down to 0.1%, which are still high in 
conventional terms may be missed unless the assay is prolonged or a novel method 
is employed.
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The determinants of disease progression are still poorly defined, complex and highly 
interdependent. Loss of CD4 T cells is likely to be a contributing factor (see below) 
and the rate of CD4+ cell loss may well be determined by virus load which is in 
turn is controlled by the CTL response. However, the inter-relationship between 
these parameters is complex (Nowak and Bangham 1996). Both virus and CTL 
destroy HIV-infected cells, but strong CTL responses could substantially reduce 
virus replication, and hence the rate of disease progression.
HIV-specific CTL decline in late stage infection
Most investigators agree that HIV-specific CTL activity becomes progressively 
harder to detect as disease progresses (Klein, et al. 1995, McMichael and Walker 
1994, Rinaldo, et al. 1995, Wolinsky, et al. 1996). In an important study, Carmichael 
et al (Carmichael, et al. 1993) showed that while EBV specific CTL were still 
present in late disease, there was a corresponding decline in HTV-specific responses. 
Another recent study, in which circulating HIV-specific CTL were directly 
quantified ex vivo, Ogg et al demonstrated a significant inverse correlation was 
observed between HIV-specific CTL frequency and plasma RNA viral load (Ogg, et 
al. 1998). The HLA-peptide tetrameric complexes used in this study provide a 
significant technical advance in enumerating antigen specific CTL (Schwartz 1 9 9 8 )  
and will help answer further questions as to the timing of CTL loss in the latter 
stages of HTV infection. The mechanism by which CTL are lost in the progression of 
disease is critical to the success of CTL adoptive transfer experiments. 
Unfortunately, there are only competing theories as to why CTL should decline but 
little hard evidence to show that loss of CTL precedes or follows the rise in viral 
load and decline in CD4 cells or how this occurs.
Is the decline in CTL activity secondary to loss of CD4+ T cell help?
The most important potential mechanism is that the loss of CTL activity is 
secondary to the loss of CD4+ T-cell numbers and impairment of their function. It is 
well established that HIV infection depletes CD4+ T cells (reviewed in (Fauci 1993, 
Fauci, et al. 1996, Pantaleo and Fauci 1995)). If the CTL response is dependent on
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Th activity, then the decline in CTL activity is inevitable if the virus is not 
completely controlled, and is likely to accelerate as CD4+ T-cell function 
deteriorates. If, as argued above, the CTL are largely responsible for the loss of 
CD4+ T-cells in slowly progressing patients, then ironically, CTL are responsible for 
their own death.
In conventional anti-viral CTL assays in vitro, the initial reactivation of human 
memory CD8+ T cells requires antigen and CD4+ T cells (Biddison, et al. 1981), 
and is facilitated by addition of IL-2 and IL-7 (Dong, et al. 1996, Lalvani, et al.
1994). In limiting dilution assays, the benefits of these additions are evident 
(Carmichael, et al. 1993). The long term maintenance of CTL in vitro requires, as a 
m inim um , IL-2 and peptide antigen (de Vries and Spits 1984, McMichael, et aL 
1986, McMichael, et al. 1988, Wallace, et al. 1982, Wallace, et al. 1982) and 
although human CTL clones can be grown in the presence of recombinant IL-2 as 
the only added cytokine (McMichael, et al. 1988), supernatants of activated T cells 
are better and imply that other cytokines are needed for optimal "help" (Wallace, et 
al. 1982). Although these are most likely to come from CD4+ T cells, there are 
other possible sources including the CTL themselves, B lymphocytes and dendritic 
cells.
Some experimental data, however, suggest that primary CTL responses in vivo may 
be less dependent on CD4+ "help". Lightman et al showed that when mice were 
depleted of CD4+ T cells by infusion of an anti-CD4 antibody, and infected with 
influenza virus, humoral responses were abolished but CTL responses remained and 
the mice could clear the acute infection (Lightman, et al. 1987). In LCMV infection 
in mice, depletion of CD4+ T cells by antibody treatment did not impair the primary 
CTL response, but the mice failed to maintain CTL memory during persistent 
infection (Matioubian, et al. 1994). However, under more rigorous conditions, 
Ewing et al (Ewing, et al. 1994) showed that in mice transgenic for an irrelevant 
TCR V-beta chain, although depletion of CD4+ T-cells in vivo greatly impaired the 
anti-Sendai CTL response, it had less effect on an anti-influenza CTL response and
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even more convincing support for the helper T cell-independence of the primary 
CTL response, comes from experiments in CD4 -/- (knockout) mice (Battegay, et aL 
1994, von Herrath, et al. 1996) and MHC II -/- mice (Hou, et al. 1995, Rock and 
Clark 1996) which have increased susceptibility to viral infections.
When CTL are primed with peptide epitopes, a consistent finding is that it is very 
difficult to prime with only class I restricted epitopes and Class II epitopes must be 
added (Sauzet, et al. 1995, Shirai, et al. 1996, Shirai, et al. 1994). As well, peptide 
priming of CTL responses in mice can be blocked by and-CD4 treatment in vivo 
further suggestion Th cell dependence (Fayolle, et al. 1991, Gao, et al. 1991). One 
explanation for these seemingly contradictory data comes from experiments on the 
roles of antigen dose and of dendritic cells in priming of CTL. Rock et al (Rock and 
Clark 1996) primed mice with particulate ovalbumin; MHC class II presentation was 
required at low antigen doses, but not at higher doses. Therefore, viruses might 
appear CD4+ T-cell independent because the amount of antigen is usually high, 
whilst antigens such as minor transplantation antigens (Hurme, et al. 1978) and 
some alio MHC-responses (Lee, et al. 1994) might depend more on CD4+ T-cell 
helper for induction of CTL responses. It is probably relevant that dendritic cells, 
which are capable of presenting particulate antigens by the class I pathway, are 
sufficient to induce primary CTL responses in vitro without T-cell help (Bhardwaj, 
et al. 1994, Young and Steinman 1990).
It should be noted that dendritic cells themselves may be infected by HIV, thus 
acquiring the ability to process and cross-present Class I epitopes and this ability to 
present epitopes is not dependent upon their productive infection (Cameron, et aL 
1992, Patterson and Knight 1987).
In summary, the experiments in mice indicate that priming with peptides or low 
dose antigen requires T-cell help, but that priming by virus infection may not. 
However, it has been shown repeatedly that the maintenance of CTL memory is 
dependent on the presence of CD4 + T cells; this could be crucial to our 
understanding of AIDS pathogenesis.
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Is there a Thl to Th2 switch during progression to AIDS?
A switch in the phenotype of CD4+ cells may also account for loss of help function. 
In 1986, Mosmann and Coffman showed that a panel of murine CD4+ T-cell clones 
could be classified according to their cytokine secretion profiles (Mosmann, et aL 
1986). Thl cells were characterized by the production of IL-2, IFN-g and TNF-6 
while Th2 cells predominantly secreted IL-4, IL-5, IL-10 and IL-13. These secretion 
patterns were subsequently termed Type 1 and Type 2 responses (Clerici and 
Shearer 1994). Not all T-cell clones exhibit such a clear dichotomy of cytokine 
production, and lymphocytes which produced a mixture of Type 1 and Type 2 
responses are referred to as ThO (Street, et al. 1990). Subsequent reports have 
confirmed the presence of Thl and Th2 phenotypes in human cells (but with a 
strong preponderance of ThO over Th2) and defined their responses to many natural 
infections (reviewed in Romagnani 1994). Type 1 responses promote cellular 
immunity while Type 2 responses bias the immune response towards antibody 
production.
Infection with HTV provokes both cellular and humoral responses in vivo. However 
neutralising antibodies appear very late in the infection (Moore, et al. 1994) and 
seem to be relatively ineffective because of virus envelope variation. Antibodies to 
other virus proteins that do not neutralise are made earlier but play an ill-defined 
anti-viral role. As discussed above, CTL are probably the key factor in control of 
disease. Clerici and Shearer first suggested that a switch from a predominantly Type 
1 response to a Type 2 response, resulting in decreased cellular immunity, may 
underlie the immune dysfunction in ADDS (Clerici and Shearer 1993). Their 
hypothesis was followed by some evidence that over the course of HTV infection 
PHA-stimulated peripheral blood lymphocytes produced increasing amounts of IL-4 
and IL-10 (Clerici, et al. 1993, Clerici, et al. 1994, Meyaard, et al. 1994). Moreover, 
the anti-HIV suppressive factor produced by the CD8+ cells of long-term survivors 
as described by Levy et al (Levy 1993, Mackewicz, et al. 1991) appears to be 
dependent on a Type 1 cytokine environment (Barker, et al. 1995). It is not known
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whether production of C-C chemokines is Thl or Th2 dependent though it is clear 
that CD4+ clones can make them (Dong et al, unpublished observations).
The Thl-2 cytokine switch has not been easily found by other groups. In particular, 
Graziosi et al looked at cytokine mRNA expression in the lymph nodes of HIV 
seropositive patients at differing stages of disease and found little change in secretion 
patterns over the course of disease (Graziosi, et al. 1994). Similarly, Maggi and 
Romagnani were unable to show an increase in Type 2 responses in infected versus 
uninfected patients using PHA or PMA plus anti-CD3 stimulated PBMC (Maggi, et 
al. 1994). They did however find a shift towards IL-4 secretion among CD8+ T-cell 
clones derived from the skin (Maggi, et al. 1994), although the relevance of this is 
unknown.
Maggi et al (Maggi, et al. 1994) and Vyakamam et al (Vyakamam, et al. 1995) 
have demonstrated that HIV preferentially replicates in the Th2 or ThO cells, whilst 
Thl cells appear relatively resistant to infection. This correlates with evidence that 
virus-induced cell death is primarily of Th2 cells whereas the Thl subset appears 
protected (Clerici, et al. 1994, Estaquier, et al. 1995). This could mean that a switch 
to an increased number of Th2 cells during infection could result in upregulated 
virus production in CD4+ lymphocytes and subsequent apoptosis. This hypothesis is 
supported by the finding that HIV infected patients with high circulating IgE levels, 
presumably as a result of Th2 activity, appear to have a worse prognosis (Israel Biet, 
et al. 1992, Lucey, et al. 1990), although in some cases this does not correlate with 
increased IL-4 levels (Vigano, et al. 1995). Thus patients whose immune systems are 
activated by atopic conditions or infections which upregulate Th2 responses may 
cope poorly with HTV infection, although further evidence is needed.
A complicating factor is that in vitro experiments do not take into account the 
complex cellular milieu in vivo. A  number of other cells, principally B-cells and 
macrophages, also secrete cytokines which modify lymphocyte responses. 
Macrophages are an important reservoir of HIV infection and whereas IL-4
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activates T-cells and upregulates lymphocyte virus production, the same cytokine 
appears has a virostatic effect upon macrophages, as do IL-10 and IL-13 (Montaner 
and Gordon 1995). Th2 cytokines therefore might not be wholly bad in HIV 
infection. If the Th2/Th0 subset of cells is preferentially infected and killed, the loss 
would result in lower concentrations of IL-4 in the lymphatic microenvironment and 
the reactivation and secretion of new virus from macrophages to renew the cycle 
(Montaner and Gordon 1995).
It is currently difficult to interpret whether infection and death of subsets of CD4+ 
lymphocytes is a result of, or the reason for, a Thl to Th2 switch - if indeed such a 
switch is real. Experiments done to date appear to present conflicting data with 
respect to a cytokine switch during the course of HIV infection. These 
disagreements illustrate the complexity of the field which is highly dependent on the 
sensitivity and reproducibility of different protocols, on the different sampling times 
and specimens and perhaps even on statistical error (reviewed in (Romagnani, et aL
1994)). More convincing is the evidence that HTV replicates preferentially in Th2/0 
cells and that the Th2 subset are more susceptible to apoptosis than Thl cells. 
However the relevance of this phenomenon in vivo is still unknown.
Do CTL become exhausted?
Lymphocytes, including CTL become exhausted as a consequence of prolonged 
high-level stimulation. An analagous situation has been described in an animal model 
transgenic for an LCMV-specific T-cell receptor challenged with high doses of 
LCMV (Moskophidis, et ai. 1993), but this was an acute phase response and there is 
no evidence that it occurs in humans. High levels of HIV-specific effector cells 
expressing the same HIV-specific TCR have been detected in peripheral blood over 
several years in two haemophiliac donors (Moss, et al. 1995), but the frequency of 
these CTL during progression to AIDS has not been studied. Recent studies of 
telomere length as an indication of replicative potential have shown that the CD8+ 
cells of HIV-infected people have significant telomere shortening (Effros, et aL
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1996). This is in contrast to the CD4+ subset (Wolthers, et al. 1996), suggesting that 
there is much greater CD8+ cell turnover and hence potential for exhaustion.
If CTL exhaustion does occur, then failure to generate new CD8+ CTL could be a 
result of dendritic cell infection or infection of CD4+ CD8+ CTL precursors in the 
thymus. However, in a recent trial of adoptive immunotherapy using HIV-specific 
CTL clones transduced with marker and “suicide” genes, HIV-infected patients with 
CD4+ counts between 200 and 400/jul were able to generate CTL specific for the 
foreign genes and eliminate the infused CTL (Riddell, et al. 1996), so at this level of 
immunosuppression effective CTL responses to new antigens can still be made.
Can CTL be infected by HTV?
Despite the lack of CD4 expression, there have been occasional reports of HIV 
infection of CD8+ cells. For example, in long-term SFV-mac-specific CTL cultures 
(Tsubota, et al. 1989), and more recently in as many as 400/million CD8+ cells 
taken from HIV-infected people in the late stages of disease (Livingstone, et aL
1996). It is possible that HIV-specific CTL become infected at the time of lysis of 
infected target cells (De Maria, et al. 1991). It has also been shown in human fetal 
thymic explants into SOD mice that CD4+8+ thymocytes can be infected with HIV 
and are then depleted; as these cells are precursors of positively selected CD8+ T 
cells, it is possible that CTL could be infected by this route. However, this seems 
unlikely to be a major mechanism because multiple cell divisions are involved, and 
infected cells would activate virus expression and be killed by virus cytopathic 
effects or by the immune response.
Does HTV escape from the CTL response?
In South East Asia, the high prevalence of the HLA-All allele among Chinese 
appears to have selected a variant of EBV that has a mutation in the 
immunodominant epitope that it presents to CTL (de Campos-Lima, et al. 1993, de 
Campos-Lima, et al. 1994). If CTL are truly important in controlling HTV infection 
and given the variability of the virus it must be inevitable that escape mutation will
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occur. The viral genome consists of 10^ nucleotides, the mutation rate is estimated 
to be 10"5 per generation (Coffin 1995) and lO^-lQlO virions are generated every 
day (Ho, et al. 1995, Perelson, et al. 1996). Thus there are lO^-lO^ point mutations 
made each day, with every possible point mutation occurring multiple times and in 
many combinations, although the vast majority of mutations result in defective 
virus. Recent evidence on the sequences of the viral proteases supports the view 
that the virus quasispecies contains vast numbers of mutants; protease escape 
mutations are there before any drug is given (Kozal, et al. 1996). Despite this 
enormous mutation rate, the database of HIV amino acid sequences shows that 
there are clear consensus sequences (Korber, et al. 1995) and nearly all patients 
examined have predominant virus sequences which are close to the consensus 
sequence (Holmes, et al. 1992, Meyerhans, et al. 1991, Phillips, et al. 1991). This 
implies that conserved sequences are selected at or around the time of transmission 
in the absence of any immune response, presumably for their transmission and 
survival characteristics.
Examination of envelope amino acid sequences in acute HTV infection demonstrates 
conservation even in the most variable part of the molecule, the V3 loop (Wolfs, et 
al. 1990, Zhang, et al. 1993, Zhu, et al. 1993). However, once the immune response 
begins to control the virus there is a diversification in the envelope sequence that 
must result largely if not entirely from selection by neutralising antibody 
(McKeating, et al. 1989, Wolfe, et al. 1990). Evidence for this comes from 
measurement of non-synonymous to synonymous or dN/dS (coding to non-coding) 
nucleotide changes in envelope sequences in macaques infected with molecular 
clones of SIV where certain amino acid changes were clearly selected (Bums and 
Desrosiers 1994, Shaper and Mullins 1993). Although antibody was almost certainly 
responsible, it has been suggested that there could be another force acting on the 
envelope (Weiss 1996). The envelope, probably the V3 region binds to a co-receptor 
as well as CD4 on T cells, CCR5 (or possibly CCR2b or CCR3) or CXCR4 
(Alkhatib, et al. 1996, Choe, et al. 1996, Doranz, et al. 1996, Dragic, et al. 1996,
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Feng, et al. 1996) and the virus could change its envelope to bind to different co- 
receptors and so change its tropism. It is possible that an increase in target cell range 
could also act as a selecting force on the envelope sequence. However, it is very 
likely that the high titre of neutralising antibody that is often present has a selective 
effect Both antibody selection and alteration in tropism could combine as a potent 
force in the pathogenesis of HTV infection.
As discussed above, the initial viraemia is controlled by the CTL response: the 
appearance of the latter occurs just as the viraemia falls (Koup, et al. 1994). The 
kinetics of these grossly expanded CTL (Pantaleo, et al. 1994, Pantaleo and Fauci
1995) are almost certainly sufficient to kill most virus infected cells before new 
virions are produced (Klenerman, et al. 1996). Selection of escape mutants may 
occur at this time. Borrow et al (Borrow, et al. 1996) and Price et al (Price, et al
1997) have both described acutely infected patients in whom there were strong 
CTL responses to single dominant epitopes. In both, escape mutants were selected 
and completely dominated the virus quasispecies within 8-10 weeks. For both 
examples, the mutant epitopes, one in Env and one in Nef, failed to bind to the 
presenting HLA molecule, HLA B44 and B8 respectively. The apparent association 
between oligoclonality in the primary response and poor outcome (Pantaleo and 
Fauci 1995) could reflect selection of such escape variants and/or over stimulation 
and exhaustion of responding T cell clones.
It should be noted that unlike extracellular escape from antibody, intracellular viral 
escape is recessive if there are multiple virus genomes within the cell. That is, when 
the cell is killed all virus variants within that cell die. However as an HIV-infected 
cell only integrates a single copy of HTV cDNA and since most of the mutations 
arise pre-integration during the reverse transcription stage, it follows that all viral 
products in the cell should have the same mutations. It is under these circumstances 
that selection by CTL can occur.
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In the original description of virus escape from (non-HIV) CTL, the infected mice 
were transgenic for an antiviral CTL TCR so that there was a monospecific selection 
force acting on the virus, LCMV (Aebischer, et al. 1991, Pircher, et al. 1990). 
Similarly, in the first trial of adoptive transfer for HTV (Koenig, et al. 1995), Koenig 
et al described a patient who was treated by infusion of very large numbers of a 
single CTL clone specific for a nef epitope presented by HLA-A3. This resulted in 
the appearance of virus with deletions in nef that eliminated the epitope. It is likely 
that the transfer of such large number of a single clone made it the dominant 
selection force. Under these circumstances a single mutation can evade the whole 
CTL response.
The descriptions of escape mutants underscore the importance of CTL in controlling 
the virus. They further suggest that lysis is an important in vivo mechanism for 
control of this virus infection; escape is very simple if the alternative is death. CD8+ 
T cells that release chemokines could also select escape mutants, but if a mutant- 
virus infected cell was next to a cell infected with wild-type virus, virus released 
from both might be equally inhibited from infecting new cells.
Do IIIY-specific CTL die by apoptosis?
The proportion of CD8+ cells expressing/oj increases during HIV infection, making 
them vulnerable to depletion by /osL-induced apoptosis (Gehri, et al. 1996). There is 
some evidence that CD8+ cells taken from people with late-stage HTV infection are 
prone to apoptosis in the presence of HTV antigens in vitro, which reduces the 
detection of HIV-specific CTL activity (Chia, et al. 1995). This is associated with 
reduced expression of the Bcl-2 protein which protects cells from apoptosis (Boudet, 
et al. 1996). Apoptosis has also been seen in the SFV models; Xu et al have found 
that many CD8+ T cells in macaques infected with a clone of SFVmac 251 showed 
spontaneous apoptosis, probably related to increased expression of Fas (Xu, et al
1997). This lysis masks the CTL response because the responding CTL die in 
culture. In the same paper, it was shown that SFV infected cells upregulate the 
expression of Fas ligand. This raises the possibility that antigen-specific CTL which
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respond to SIV-infected cells and which express Fas are susceptible to Fas-mediated 
apoptosis. This would constitute another means of viral escape outside the antigen- 
presentadon pathway.
The mechanisms discussed above are not mutually exclusive and all could contribute 
to the repeatedly made observation that the CTL response that can be demonstrated 
in vitro fails as the CD4+ T cell level falls below 200/ml. However the relative 
contributions of each of these processes is important to understand because the 
implications for the treatment may be quite different. If the impairment of CTL 
activity in vitro is due to loss of CTL precursors, perhaps due to clonal exhaustion 
(Moskophidis, et al. 1993, Pantaleo, et al. 1994, Pantaleo and Fauci 1995), an 
effective treatment might be to replace the CTL by adoptive transfer (Koenig, et aL 
1995, Riddell, et al. 1996, Riddell and Greenberg 1995) assuming that the 
adoptively transferred cells themselves are not exhausted. On the other hand, if it is 
secondary to loss of CD4+ T cell activity, possibly including a switch from Thl to 
Th2 responses, treatment would be replacement of CD4+ T cells - providing a 
suitable donor was available (Walker, et al. 1993) or infusion of IL-2, assuming that 
this is the key cytokine for effecting CTL activity. Some support for this view 
comes from Greenberg et al who have treated bone marrow transplant recipients 
with CMV-specific CD8+ CTL clones (Riddell and Greenberg 1995, Riddell and 
Greenberg 1995, Walter, et al. 1995) They found much better survival of the 
infused clones when there was an ongoing and-CMV Th response (Walter, et aL
1995).
Adoptive immunotherapy of viral infections
The adoptive transfer of autologous Class I MHC-restricted cytotoxic T-lymphocyte 
(CTL) clones or lines to patients infected with the human immunodeficiency virus 
(HIV) has been based on the success of this therapy in the control of other viral 
infections in humans (Riddell and Greenberg 1995) Apart from the obvious 
intention to treat patients, this type of study directly addresses the role of CTL in 
HTV infection.
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In uncontrolled trials, donor derived CMV-specific CTL clone infusions protected 
bone marrow recipients from CMV disease until reconstitution of immune responses 
(Riddell, et al. 1992, Walter, et al. 1995). These studies also demonstrated the 
relative safety of lymphocyte infusions, the ability of transferred cells to survive up 
to 12 weeks in most patients and the apparent dependence of infused CTL on 
CMV-specific CD4+ lymphocytes for survival and proliferation. Infusion of donor 
leucocytes or donor derived CTL lines also appear to be effective for the treatment 
of EBV proliferative disorders in bone-marrow recipients (Papadopoulos, et aL 
1994, Rooney, et al. 1995) and confirm the relative safety of infusions and the 
relative long-lived nature of infused cells.
Early experiments with adoptive transfer of lymphocytes for HIV infection have 
been discouraging. Ho et al attempted to augment CD8+ responses by infusing 
large numbers of autologous, polyclonally expanded CD8+ cells that had be 
obtained by leucopheresis. The protocols for expansion used only high doses of IL-2 
without antigen-specific T-cell stimulation, thus failing to enrich for HIV positive 
cells. Such expansion protocols may be expected to aid in the CTL to a number of 
other infections but this was not explored. (Ho, et al. 1993). The therapy was well 
tolerated but significant anti-HIV effects were not observed. Other groups who have 
tried similar expansions and infusions have claimed improvement in opportunistic 
infections (Klimas, et al. 1994). Koenig et al transferred large numbers (around 
1010 cells) of a ^/-specific clone to an HIV-infected patient (CD4 count around 
400/pl) twice over a period of 14 months (Koenig, et al. 1995). As expected the 
number of CD8+ cells was increased post-transfusion but surprisingly a matching 
rise in CTL specific lysis was not seen. This is probably because the patient still 
possessed high baseline activity against the nef epitope or, less likely, because the 
infused cells rapidly distributed to the lymphatic system with the displacement of 
non-Tief-specific cells into the periphery. Unexpectedly, there were transient 
increases in virus load following both infusions and an apparent concomitant decline 
in CD4+ cell counts. The first infusion was given with a massive dose of IL-2 which
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probably contributed to the virus replication by activating CD4+ T cells in vivo. 
However a similar rise in virus load was observed after the second infusion without 
IL-2. There was one direct effect of the infusion: sequencing of viral clones from the 
patient revealed a selection for viruses deleting part or all of the targetted nef 
epitope. This implies that the infused CTL were active against the virus but - 
possibly because they were monoclonal - they were ultimately ineffective. The 
patient subsequently died of AIDS.
Riddell et al have transferred Gag-specific clones to six patients with HTV (Riddell, 
et al. 1996). As a safety measure cells were genetically modified to carry both the 
hygromycin phosphotransferase gene and the Herpes simplex virus thymidine 
kinase (HSV-TK) gene which could, if required, efficiently phosphorylate 
gancyclovir and eliminate the transfused cells. Unfortunately the infused cells 
appeared to express HSV-TK resulting in a Class I HLA restricted CTL response 
and elimination of the foreign cells following the second infusion given two weeks 
after the first. At least the study showed that patients with CD4+ counts of around 
200/pl can make primary CTL responses to a novel antigen. Data on Gag-specific 
CTL activity or virus loads after the first infusion were not published.
From the limited data presently available therefore, adoptive transfer of CTL does 
not appear to provide significant benefit. Administration of two or more clones may 
decrease the likelihood that viral mutants arise and large doses of simultaneous IL-2 
may be harmful. This raises the problem of survival of the infused CTL in the 
recipient; data from CMV-specific CTL transfer shows that they last longer in the 
presence of Th activity. This is unlikely to be present in recipients with low CD4+ T- 
cell counts, the group with low CTL activity who might benefit from the transfer. 
The success or failure of CTL infusions will depend on the critical mechanisms of 
viral control. Comparison of adoptive transfer between HTV and other non-HTV viral 
infections may not be valid. In the case of CMV or EBV, cellular immunity which 
normally controls latent virus is absent because of bone marrow ablation and CTL 
infusions replace this function until host immunity is restored. In the case of HIV
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host immunity is rarely if ever restored and the primary pathology is of the immune 
system. Thus long-lasting effects will be needed, making the role of accessory cells 
and factors critical.
Other mechanisms of viral control may also render CTL infusion therapy 
ineffective. For example, if a population of CD8+CD28- cells are primarily selected 
by ex vivo expansion methods, these cells when infused may be susceptible to 
apoptosis in vivo or fail to function adequately (Levine, et al. 1996). A recent report 
from Xu et al showed that in in vitro, wild type SFV but not a nef mutant virus 
leads to an increase in FasL expression on infected cells (Xu, et al. 1997). Thus the 
expression of FasL may protect infected cells from CTL attack, killing viral specific 
CTLs in the process providing a route for escaping the immune response. If such a 
mechanism exists for HIV, adoptive transfer of CTL may simply not work. The 
capacity of CTL to proliferate in vivo is also important and may be dependent on 
unidentified inhibitory factors (Bell and Shand 1975) or lymph node architecture 
which is usually destroyed in AIDS. Moreover there may remain a pool of latently 
infected cells which are sequestered from CTL lysis (Chun, et al. 1995) or which 
express viral antigens defectively (Tsomides, et al. 1994). In these cases CTL 
infusions are unlikely to stem the course of disease. Finally, the mechanisms by 
which CTL inhibit viral replication represent a combination of antigen-triggered 
CTL lysis as well as antigen-triggered chemokine secretion. Therefore it may be 
necessary to determine whether antigen-specific clones are those which produce 
inhibitory chemokines.
Immune reconstitution of HIV-infected patients by adoptive transfer of syngeneic 
whole lymphocytes or fractionated Class II MHC-restricted CD4+ lymphocytes has 
also been attempted. In a report from Bex et al (Bex, et al. 1994), an uninfected 
twin was first vaccinated with recombinant envelope protein from HIV and, 
following demonstration of envelope-specific CTL, his peripheral blood lymphocyte 
population was obtained by leucopheresis and transfused into the infected twin who 
had an undetectable CD4+ count. No changes in the clinical, immunological or
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lymphocyte parameters of the recipient were noted following the first infusion. A 
second infusion was performed using lymphocytes pre-incubated with HTV gpl60. 
After the second transfer there was a increase in total lymphocyte counts (both 
CD4+ and CD8+ cells) and an improvement in functional proliferation assays. 
However, there was also an increase in viral load following both transfer. The 
infected twin subsequently died of unrelated causes.
In a study from Lane et al (Lane, et al. 1990), 16 HIV seropositive twins were 
treated with zidovudine combined with six infusions of peripheral blood 
lymphocytes obtained from the seronegative twin and bone marrow transplantation 
at the end of the study. After lymphocyte infusions, there was an increase in the 
percentage of CD4+ cells present and an increase in the number of patients with 
delayed-type hypersensitivity reaction to tetanus toxoid. However, there was no 
change in the clinical status of the patients and the immunologic changes were 
transient. A second study which has recently begun is an ongoing phase VU trial 
designed to examine the safety and efficacy of repeated infusions of activated, ex- 
vivo expanded syngeneic T-lymphocytes in HIV infected twins. Some data on five 
patients have been collected (Clifford Lane, personal communication). In one patient 
there was a marked rise in plasma virus coincident with each infusion. No further 
data is available.
Restoration of T-cell repertoire may be possible but this has yet to be demonstrated. 
It seems likely that transfer of activated CD4+ lymphocytes would result in the 
infection of infused cells and a subsequent rise in viral load. Direct transfer of 
lymphocytes without IL-2 or anti-CD3 activation may represent a better alternative.
Overall, immunotherapy either of anti-HIV CTL clones or more general attempts to 
restore the immune system is currently unproven, expensive and laborious to carry 
out. At present it cannot compete with the promising reductions in virus load 
achieved by the newer anti-retroviral drugs. However it is quite likely that, while the 
drugs may control the virus in the short or medium term, there could be a place for
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immunotherapy in attempting to repair greatly damaged immune systems to 
facilitate longer term management of patients.
52
CHAPTER TWO
Adoptive Transfer Of Syngeneic Lymphocytes From An HIV- 
Uninfected Twin To His HIV-Infected Sibling
Introduction
Bone marrow transplantation in AIDS
The transition from asymptomatic HIV infection to AIDS is usually associated with 
the loss of CD4+ cells and an accompanying state of immune deficiency. Attempts 
to reconstitute the immune system either by the administration of immune 
enhancing cytokines such as alpha interferon (Krown, et al. 1986, Krown, et aL 
1987, Andrieu, Lane et al, Rook et al) or by the transfusion or transplantation of 
cells have not yet been able to prevent progession to AIDS and death (Bex, et aL 
1994, Contu, et al. 1993, Davis, et al. 1983, Giri, et al. 1992, Hassett, et al. 1983, 
Holland, et al. 1989, Lane, et al. 1984, Lane, et al. 1990, Vilmer, et al. 1987). 
However, because all of the trials or case reports vary in a number of critical 
respects, they do not rule out the possibility that an optimal regimen of bone 
marrow transplantation (BMT) or cell transfer combined with potent anti-retroviral 
drugs could ameliorate disease.
Some encouraging results have been obtained following BMT in several patients 
infected with AIDS. A 41 year old HTV positive male with an immunoblastic 
lymphoma was treated with zidovudine, cyclophosphamide and total body 
irradiation prior to an allogeneic marrow transplantation (Holland, et al. 1989). 
Engraftment occurred on day 17 with demonstrated chimerism. Both viral culture 
and PCR amplication of PBMC and bone marrow cells were negative for HTV 32 
days post-transplantation. However, the patient died 47 days post-transplantation 
due to tumour relapse. Autopsy specimens were negative for HTV by PCR.
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A 25 year old woman with AIDS was treated with zidovudine, busulphan and 
cyclophosphamide prior to syngeneic bone marrow transplantation (Contu, et aL 
1993). Engraftment occurred after 18 days and tests for HTV were negative after 30 
days. A second transplant from the same donor was ineffective and the patient died 
from acute respiratory failure 10 months after transplantation. However, p24 
antigen and PCR for Env, Gag and Pol DNA became negative 30 days after 
transplantation and HTV serum antibodies measured by ELISA and Western blot 
began to decrease after 2 months, becoming completely negative 4 months after 
BMT. As with the report by Holland et aL PCR on autopsy tissues (skin, lungs, 
brain, liver, spleen) was negative for Env, Gag, and Pol.
An unpublished case of xenotransplantation was attempted on a 38-year-old patient 
with AIDS (Flicker 1996). The patient was given total lymphoid irradiation (lU ) 
and a triple combination of anti-retroviral agents (AZT, lamivudine, and indinavir) 
prior to transplantation with baboon bone marrow. Despite their similarity to human 
cells, baboon cells cannot be infected with HTV. The graft was quickly rejected but 
surprisingly the patient's condition improved with a decrease in viral loads and 
increased CD4+ counts.
These cases and others are summarised in Table 1. Taken together, these reports 
suggest that aggressive anti-viral therapy combined with a conditioning program 
can, in certain cases, drastically reduce or eliminate virus in vivo. Pre-transplantation 
conditioning by radiation or chemotherapy appears to be helpful both in promoting 
engraftment of cells and in eliminating cellular stores of HTV. Certainly, total ablation 
of white cells would destroy nearly all of the viral reservoir; moreover, engraftment 
and de novo proliferation of lymphocytes may result in an anti-viral effect.
Adoptive transfer of syngeneic lymphocytes
Immune reconstitution of HIV-infected patients through the adoptive transfer of 
syngeneic lymphocytes has previously been attempted by groups at the National 
Institutes of Health (Lane, et al. 1990) and in the Netherlands (Bex, et al. 1994). In
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the first NIH study, 16 HIV seropositive twins were treated with the anti-viral drug 
zidovudine combined with six infusions of peripheral blood lymphocytes obtained 
from seronegative twins and bone marrow transplantation. After lymphocyte 
infusions, there was an increase in the percentage of CD4+ cells present and an 
increase in the number of patients with a restoration of delayed-type hypersensitivity 
(DTH) reaction to tetanus toxoid. However, there was no change in the clinical 
status of the patients and the immunologic changes were transient. The second NIH 
study, which was started recently, is an ongoing phase VYL trial designed to examine 
the safety and efficacy of repeated infusions of activated, ex-vivo expanded 
syngeneic T-lymphocytes in HIV infected twins. Limited data on five patients has 
been released. In one patient there was a marked but transient rise in plasma virus 
after each infusion. No further published data is currently available, but personal 
communication from Dr. H.C. Lane, NIH, suggests that the infusions have been 
well-tolerated, and the patients in the study have maintained or elevated CD4+ 
counts following therapy, with evidence of improved CD4+ cell function.
In the study from the Netherlands, an uninfected twin was first vaccinated with 
recombinant envelope protein from HIV, and following the demonstration of 
envelope-specific CTL, his peripheral blood lymphocyte population was obtained by 
leucopheresis and transfused into his brother, who had a CD4+ count of zero. No 
changes in the clinical or laboratory status of the recipient were noted after the first 
infusion. A second infusion was performed using lymphocytes pre-activated with 
HTV envelope protein. After the second transfer there was an increase in total 
lymphocyte counts (in both CD4+ and CD8+ cells) and an increase in functional 
proliferation assays. However, there was also a marked increase in viral load 
following the second transfer. The infected twin subsequently died of unrelated 
causes.
We have attempted to restore the CD4+ and CD8+ lymphocyte subsets in an HIV- 
infected individual by the adoptive transfer of syngeneic lymphocytes obtained from 
the patient's HIV-seronegative twin. Serial lymphocyte counts suggest that the in
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vivo expansion of CD4+ and CD8+ lymphocytes occurred. TCR V-beta repertoire 
analysis by spectratyping reveals a distorted CD8+ repertoire in the HIV-infected 
twin, which remained relatively stable despite lymphocyte proliferation.
Methods
Patients
The donor was a 34 year old white, male heterosexual, non-injecting drug user 
serologically negative for HIV, HBV, HCV, CMV and syphilis and seropositive for 
EBV and VZV. The monozygotic twinship was confirmed by microsatellite 
sequencing (Dr. Annette Jepson).
The recipient was a homosexual found to be HIV antibody positive in November 
1985 on a routine screening test in his GU clinic. There was no history of 
seroconversion illness and no immunological tests were done at that stage. In 1992, 
he had a full medical examination which revealed generalised lymphadenopathy and 
oral hairy leucoplakia. His CD4+ count was 400/pl. When he was seen in 1995, he 
had oro-esophageal Candida, loss of weight, low grade fever, night sweats and 
recurrent genital Herpes simplex infection. His CD4+ count was now 40/pl, a full 
blood count showed pancytopenia and a bone marrow biopsy confirmed 
Mycobacterium avium-complex (MAC) infection. He was treated with rifabutin, 
ciprofloxacin and clarythromycin for the mycobacterial infection, fluconazole for 
fungal prophylaxis, acyclovir for recurrent Herpes zoster infection as well as 
trimethoprim-sulfamethoxazole for Pneumocystis carinii prophylaxis. In addition, he 
had previously bee prescribed AZT and DDC although it was unclear if he 
continued to take these regularly. Serological tests prior to cell transfer showed that 
he was HBV, HCV, and Toxoplasma gondii negative but CMV and EBV positive. 
At the time that this study was initiated, his CD4+ lymphocyte count was 60/pl 
although but the time of cell infusion, this had decreased to 4/pl and he was severely 
cachectic. At that time, he also had documented fever, cough, diarrhea and oral 
hairy leucoplakia and had laboratory confirmed infections with Candida albicans,
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MAC and Herpes zoster. The patient died six months after the initial infusion. No 
autopsy was done.
Leucopheresis
Leucopheresis was done using a COBE Spectra Apheresis System (COBE BCT, 
Inc. Lakewood, Colorado). Briefly, the donor twin was anticoagulated and blood 
was collected through a peripheral venous line at 40-60 ml/minute into cell separator 
which separated blood components on the basis of density and weight. The 
lymphocyte fraction was retained and the non-mononuclear cell components were 
returned to the patient via a second peripheral vein catheter site. The mononuclear 
cells obtained had greater than 90% purity.
TCR repertoire bv flow cytometry
The monoclonal antibodies used for TCR V-beta (VP) staining are listed in Table 2. 
Frozen PBMC were thawed in PBS and counted. Approximately 100,000 cells 
were pelleted and incubated with the primary anti-TCR antibody for 30 minutes at 
4°C. The cells were washed twice in PBS/Azide and co-incubated with a secondary 
rabbit anti-mouse FTTC conjugated antibody (DAKO) and an anti-CD8+ PE 
conjugated monoclonal antibody (DAKO). Two-colour flow cytometry was 
performed on a FACScan flow cytometer (Becton-Dickenson) and 10,000 events 
were collected of each staining reaction. Data was analysed using Cellquest software.
TCR repertoire by spectratyping
The primers used for PCR spectratyping are listed in Table 3 and the method of 
Gorski was used (Gorski, et al. 1995). For CD8+ cell analysis, cells were negatively 
selected with magnetic beads coated with anti-CD4+ (Dynal) and then positively 
selected by anti-CD8+ coated magnetic beads (Dynal). Cell separation provided 
>95% purity by flow cytometric analysis. Approximately 1 million PBMC were 
lysed in RNAzol and chloroform followed by centrifugation and isopropanol 
precipitation. Total RNA was reverse transcribed with AMV reverse transcriptase 
and the resulting cDNA was diluted in ddH20 and used for amplification. The CP3'
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Table 3: Oligonucleotide primers used for spectratyping
Primer 5' - 3'
CbR CTT CTG ATG GCT CAA AC A C
Vbl CAA CAG TTC CCT GAC TTG C AC
Vb2 TC A ACC ATG CAAA GCC TGA CCT
Vb3 TCT AGA GAG AAG AAG GAG CGC
Vb4 CAT ATG AGA GTG GAT TTG TC A TT
VbS.l TTC AGT GAG AC A CAG AGA AAC
Vb5.2 CCT AAC TAT AGC TCT GAG CTG
Vb6 AGO CCT GAG GGA TCC GTC TC
Vb7 CTG AAT GCC CCA AC A GCT CTC
Vb8 TAC TIT AAC AAC AAC GIT CCG
Vb9 AAA TCT CCA GAC AAA GCT CAC
VblO CAA AAA CTC ATC CTG TAC CTT
V bll ACA GTC TCC AGA ATA AGG ACG
Vbl2 GAC AAA GGA GAA GTC TC A GAT
Vbl3.1 GAC CAA GGA GAA GTC CCC AAT
Vbl3.2 GTT GGT GAG GGT ACA ACT GCC
Vbl4 TCT CGA AAA GAG AAG AGG AAT
Vbl5 GTC TCT CGA CAG GCA CAG GCT
Vbl6 GAG TCT AAA CAG GAT GAG TCC
Vbl7 CAC AGA TAG TAA ATG ACT TTC AG
Vbl8 GAG TCA GGA ATG CCA AAG GAA
Vbl9 CCC CAA GAA CGC ACC CTG C
Vb20 TCT GAG GTG CCC CAG AAT CTC
Vb21 GAT ATG AGA ATG AGG AAG CAG
Vb22 t c a  n r  c g t  n r  a t g  a a a  a g a  t g c
Vb23 CAG AGA AGT CTG AAA TAT TCG A
oligonucleotide primer was end-labelled with y-P32 for one hour at 37 °C in a 
reaction buffer containing 20 pmoles of primer, T4 polynucleotide kinase, IX 
reaction buffer and 5 pCi of y-P32. PCR cycling conditions were 94°C X 5 minutes 
for 1 cycle, 94°C x 1 minute, 62°C x 1 minute, 72°C x 1 minute for 35 cycles and 
1 cycle, 94 °C x 1 minute, 62°C x 1 minute, 72°C x 10 minutes for 1 cycle. 4 pi of 
PCR product was diluted with 4 pi of formamide stop buffer and loaded onto a 6% 
acrylamide gel and subjected to electrophoresis at 200V for 2 hours. The gel was 
dried and exposed to a phosphoro-imaging plate overnight at room temperature. 
The plate was scanned into a phosphorimager (Molecular Dynamics) and the bands 
were analysed using Image-Quant software.
Virus loads
EDTA anticoagulated peripheral blood was separated by centrifugation and plasma 
immediately frozen. HTV virus load was determined on plasma aliquots using an RT- 
PCR method (Roche Amplicor).
Results
Leucopheresis
The leucopheresis procedure was well tolerated and the donor suffered no adverse 
physical effects. A total of 10 billion WBC was obtained from peripheral venous 
blood of which 54% were CD3+ (Table 4). Thus, a total of 4.8 billion lymphocytes 
was obtained. The proportion of CD3+CD4+ lymphocytes was 29% and the 
proportion of CD3+CD8+ lymphocytes was 24%, corresponding to absolute values 
of approximately 2.6 billion and 2.2 billion cells respectively. The cells were infused 
into the recipient within 16 hours of leucopheresis. Viability of the cells less than one 
hour before infusion, as determined by trypan blue staining was greater than 99%.
Clinical outcome
Lymphocytes obtained by leucopheresis were resuspended in 250 mis of normal 
saline and infused intravenously into a peripheral vein via a pump infusion setup
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over a 30 minute period. The infusion was well tolerated and the patient showed no 
adverse effects. There were no changes in pulse rate, respiratory rate, blood 
pressure or body temperature. Blood samples were drawn shortly before infusion 
and at 1, 2,4, 8 and 24 hours after infusion as well as at 28 days and 45 days post- 
infusion. At the time of infusion the patient was afebrile although in the days 
preceding the infusion he had episodes of fever and diarrhea. Clinical improvement 
following infusion was suggested by a loss of fever for weeks following the infusion, 
improvement in diarrhea and normalization of platelet counts (personal 
communication, Dr. Rabindram, Swindon General Hospital).
Hematological. Immunological and Virological Results
Blood samples were taken according to the schedule in Table 5 and sent for routine 
clinical laboratory testing. A sample from the donor twin obtained prior to 
leucopheresis and a sample of the leucopheresis cells were also submitted. A full 
blood count as well as flow cytometry to determine the proportion of CD4+ and 
CD8+ cells was performed on the samples. Baseline hematology counts showed 
anemia and pancytopenia. An absolute CD4+ lymphocyte count of 4/pl (2% of total 
lymphocytes) rose to 29/pl (14% of total lymphocytes) one hour after infusion and 
then decreased thereafter. However, on day 28 the CD4+ count had risen to 120/pl 
before falling to 9/pl at day 45 post-infusion. The absolute CD8+ lymphocyte count 
also rose from a baseline value of 146/pl to 1220/pl at day 28 and by day 45 had 
decreased to 830/pl. The proportion of CD25 (IL-2Ra) positive lymphocytes did not 
change before or after infusion. Double staining of lymphocytes for CD4+ and 
CD25+ or CD8+ and CD25+ was not done.
The plasma concentration of HIV RNA was determined on the HIV-infected twin 
(Table 5). Plasma virus RNA levels decreased nearly one-logfold one hour post 
infusion from a baseline of 1.5 million copies/ml to 350,000/ml. This rose 
subsequently to a concentration of 1 million copies/ml at day 45.
59
Ta
ble
 
5: 
H
em
at
ol
og
ic
al
, 
im
m
un
ol
og
ic
al
 a
nd 
vi
ro
lo
gi
ca
l 
lab
or
ato
ry
 
m
ar
ke
rs
 
be
fo
re 
and
 
aft
er 
the
 
ad
op
tiv
e 
tra
ns
fe
r 
of 
sy
ng
en
eic
 
ly
m
ph
oc
yt
es
.
73m7f
+ oo vo ^On On CO
CO NO o—' r- coOn O On 00
o
o
73
00(N CO (NOn m CN O 04 CN ^co oo Z
o o oo On o 04r- cn C4 04 z
J5Th<N
+
in in 
O I on co ^ 00 CO 00 00
m oo r~oo Tf- co<N <N On (N
O
00ON
J3
00
+ p cn r~(N oo co r- Th
o co «—iin co o ONO in cs m s00
(-1
? r- < ON <N Z m o o 1 on Th oo
m m  ThO NO NO 04 Th co ^  co
o
m
JC04
+ ^  P  OO CO ON O' O O^  ON in oo o-
o on oo—> m no om Th cn 'd- §m
-C
+ "t P m 0 0 ^ 0 0 1 NO Th O' 04 r—I O T—I VO ,-H
On O OO 00 ON 04 1 04 1
Omco
I ^  P m oo y—* on
î ï
I
!
O O ^ On o) 00 ON
Th oo me e g
O 04 NOoo vo Th
3. =L ZL
!
Û
00
Q
U U
§
2 1
^  §3
I 8
Bl
oo
d 
sa
m
pl
es
 
we
re
 
ob
ta
in
ed
 
fro
m 
the
 
H
IV
-p
os
iti
ve
 
pa
tie
nt
 b
efo
re
 
an
d 
aft
er
 
(fr
om
 
1 
ho
ur
 
to 
45 
da
ys
 
po
st
-tr
an
sf
er
) 
ad
op
tiv
e 
tr
an
sfe
r 
of 
sy
ng
en
ei
c 
ly
m
ph
oc
yt
es
. 
Sa
m
pl
es
 
we
re
 
as
sa
ye
d 
for
 
he
m
og
lo
bi
n 
(H
gb
), 
to
ta
l 
wh
ite
 
bl
oo
d 
ce
lls
 
(W
BC
) 
an
d 
pl
at
el
et
s 
by 
sta
nd
ar
d 
cl
in
ic
al
 l
ab
or
at
or
y 
m
et
ho
ds
. 
In 
ad
di
tio
n,
 f
low
 
cy
to
m
et
ry
 
wa
s 
pe
rf
or
m
ed
 
to 
de
te
rm
in
e 
the
 
pr
op
or
tio
n 
of 
C
D
3,
 C
D
4,
 
CD
S 
an
d 
CD
25
 
po
sit
iv
e 
ce
lls
 
in 
ea
ch
 
sa
m
pl
e.
 A
bs
ol
ut
e 
va
lu
es
 
of 
C
D
3,
 C
D4
 
and
 
CD
S 
ly
m
ph
oc
yt
es
 
we
re
 
the
n 
ca
lcu
la
te
d 
an
d 
ex
pr
es
se
d 
pe
r 
cu
bi
c 
m
ill
im
et
re
 
(p
i).
 N
A 
= 
no
t 
av
ai
la
bl
e
Ta
ble
 
6: 
TC
R 
V-
be
ta 
fa
m
ili
es
 d
ete
rm
in
ed
 
by 
flo
w 
cy
to
m
et
ry
i
s
JS
9
Û
<
Q
c2
m r~ oo en xf ON en < en 5: < < < m < xf en 00
en NO — : 00 en r- ON <o z q z z z
q
z
OO Xf NO
CN o d d d <N d d
ON (N en m r~ O n 00 NO < xt <N < < < < CN
r- m en CN in Xf 2; CN q 2 2 2 On2 q xf enoi in xh en 1 Xf (N oi NO oi 2
o o s o O N O o o » n q o q < r n < N <; < < v q < T } ; p f O <
o o v o o o v o o o T f v o r - w n v o c s t N o o o N t ^ ^ c o o v o r ^  
^ v d M ' - i d Ô C N ^ Ô C N ' t o i K Ô ^ Ô ' - ^ C N C S Ô
(^ 0, i ovovq( Nr : v o < o q ^ < < < « n < o o o ^ - H <
O O C N O O - H C N I O ^ O ^ ^ ^ Z ^ Z 0 0 0 ^
v o m o o o o o r - o s o o ’sj-
c N « n o N c s ^ d ^ ^ d ^ r ~ o m o o o T t m o o m < D  c n c n ^ r ^ ' —<’- ^ d o i ( Nc n ' —<
in<DONONmONcx)OON’7}-c<i c n d ^ c N c N O ' ^ t m —<vdd (N xh cn cn rn d ' —« c n d c Nc n c n ^
^ e N m i n r ’- r - o o o x ^ c N ' —' C N x t - v o r - o o o m c N c o
$ e s f £ £ f S i i i i g g g i $ ^ $ $
Pe
ri
ph
er
al
 b
loo
d 
m
on
on
uc
le
ar
 
ce
lls
 
(P
BM
C
) 
we
re
 
ob
ta
in
ed
 
fro
m 
the
 
re
cip
ien
t 
at 
the
 
in
di
ca
te
d 
tim
ep
oi
nt
s, 
sta
in
ed
 
wi
th 
flu
or
es
ce
nt
-la
be
lle
d 
an
tib
od
ie
s 
sp
ec
ifi
c 
for
 d
iff
er
en
t 
TC
R 
V-
be
ta
 
fa
m
ili
es
 
an
d 
qu
an
tif
ied
 
by 
flo
w 
cy
to
m
et
ry
. 
Va
lu
es
 
re
fer
 
to 
the
 
pe
rc
en
ta
ge
 
of 
to
ta
l 
ce
lls
 
st
ai
ni
ng
 
wi
th 
a 
pa
rt
icu
la
r 
TC
R 
V-
be
ta
 
an
tib
od
y.
 
A
bb
re
vi
at
io
ns
: 
Vb
 
= 
V 
be
ta
, 
LK
 
= 
do
no
r 
PB
M
C
, 
AF
 
Pr
e 
= 
re
cip
ien
t 
PB
M
C 
pr
ior
 
to 
ad
op
tiv
e 
tr
an
sfe
r, 
AF
 
+2
4h
 
= 
re
cip
ien
t 
PB
M
C 
24 
ho
ur
s 
aft
er
 
ad
op
tiv
e 
tr
an
sfe
r 
an
d 
ÀS
D 
= 
sta
nd
ar
d 
de
vi
at
io
n.
 M
ea
n 
% 
re
fer
s 
to 
the
 
me
an
 
va
lu
es
 
ob
ta
in
ed
 
fro
m 
ten
 
he
alt
hy
 
in
di
vi
du
al
s. 
St
an
da
rd
 
de
vi
at
io
ns
 
fro
m 
the
 
me
an
 
wh
ich
 
are
 
> 
3 
ha
ve
 
be
en
 
bo
ld
ed
. 
NA
 
= 
no
t 
av
ai
la
bl
e
Repertoire analysis by flow cytometry
CD4+ analysis by flow cytometry was not technically possible because of an 
insufficient quantity of CD4+ lymphocytes present in the peripheral blood. Flow 
cytometric analysis of the CD8+ TCR subset was done using V-beta family specific 
monoclonal antibodies. A mean percentage of V-beta subsets was determined by 
collecting samples from ten healthy individuals. Expansions have previously been 
defined as percentages which fall outside 3 standard deviations from the mean as 
calculated by assaying the repertoires of healthy individuals (Rebai, et al. 1994). 
Using this definition, very few V-beta expansions or deletions were detected by 
monoclonal antibodies in either the CD8+ cells derived from leucopheresis of the 
healthy twin or from the CD8+ lymphocytes before and after infusion in the HTV+ 
twin (Table 6).
Repertoire analysis by spectratype
The TCR V-beta repertoire was also determined by spectratyping on the CD4+ and 
CD8+ subset of cells obtained from the leucopheresis cells (shown in Figure 5) and 
on the CD8+ subset in the recipient's peripheral blood mononuclear cells at Time 0, 
+24 hours and +28 days (shown in Figure 6).
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Figure 5: Donor T cell repertoire determined by spectratyping
PBMC obtained from the donor by leucopheresis were purified using magnetic 
beads conjugated with antibodies to either CD4 or CDS. Complementary DNA 
(cDNA) synthesized from either the CD4+ or CD8+ lymphocyte fractions were 
then subjected to TCR V-beta family "hot" PCR using a forward primer specific for 
V-beta germline sequences and a reverse primer specific for the TCR constant 
region. The PCR products were then separated by acrylamide gel , exposed to a 
radioactivity-sensitive screen and scanned into a phosphorimager. Each different 
sized band within a TCR V beta family represents an amplified cDNA TCR V-beta 
segment with a unique variable joining and/or diversity region.
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Figure 6: Recipient CD8+ T cell repertoire determined by spectratyping
PBMC obtained from the recipient at the indicated timepoints, before and after 
adoptive transfer, were purified using magnetic beads conjugated with antibodies to 
either CD4 or CDS. There were insufficient CD4 cells to generate cDNA and only 
cDNA obtained from CDS cells was subjected to spectratyping. Complementary 
DNA (cDNA) synthesized from either the CD8+ lymphocyte fractions was 
subjected to TCR V-beta family PCR as described in Figure 5. Arrrowheads 
indicate unchanged repertoire (V-beta 2.1) and expansion of existing repertoire (V- 
beta 23). Asterisk indicates formation of a new repertoire.
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There is neither a close correlation between the CD4+ and CD8+ repertoire 
obtained from the same individual or perturbations in the repertoires obtained from 
this healthy individual. In accordance with previous observations, there is also little 
correlation between the TCR repertoires of the healthy donor and his HTV+ 
monozygotic twin (Hawes, et al. 1993, Rebai, et al. 1994).
Discussion
Lymphocyte expansion and clinical course
There were encouraging signs in our patient that the transferred syngeneic 
lymphocytes were actively proliferating. By the day 28 after cell transfer, the CD4+ 
lymphocyte count had risen from 4/pl to 120/pl and the CD8+ lymphocyte count 
had risen from 146/pl to 1220/pl. If these expanded cells were functional, at least a 
temporary benefit could be attributed to the infusions. The lymphocyte proliferation 
present in both subsets could be ascribed to encounters with novel or recall 
antigens, followed by activation and proliferation secondary to CD4+ mediated IL-2 
production. For example, since the recipient was actively infected with VZV (Herpes 
zoster) and the donor was serologically positive for VZV, reactivation of VZV- 
specific CD4+ and CD8+ memory cells present in the infusion could produce an 
extensive proliferation of lymphocytes. The same argument can be made for EBV 
since the recipient was suffering from oral hairy leucoplakia and the donor was EBV 
seropositive. Any EBV-specific memory cells present in the infusion would be 
expected to undergo clonal expansion upon encountering active EBV infection. In 
this regard, the infused cells may have played a role in augmenting the patient's 
immune response to MAC. Prior to infusion, the patient (who was non-compliant 
with his anti-mycobacterial drug regimen), suffered from fever, chronic diarrhea and 
pancytopenia. These symptoms improved after the infusion and in particular, his 
platelet count rose from a baseline level of around 95/pl to 223/pl two months after 
the infusion suggesting improved production of megakaryocytes. Alternatively, the 
cells may have simply been repopulating depleted lymph nodes where they would 
be expected to undergo expansion in order to maintain lymphocyte homeostasis.
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Extensive repopulation of lymph nodes by post-thymic T-cells has been 
demonstrated in several murine models of adoptive transfer (Rocha 1987; Miller and 
Stutman 1984; Bell, et al. 1987). In most cases, the repopulation falls short of 
normal numbers of lymphocytes, although functionally the lowered populations do 
not appear to result in an abnormal host immune response. Perhaps more 
importantly, the recipient mice in all the experiments were irradiated, depleting them 
not only of lymphocytes but also of other factors which may inhibit lymphocyte 
expansion (Bell and Shand 1975). Whether HIV-mediated destruction of lymph 
nodes provides a suitable environment for lymphocyte expansion is not known 
although the evidence is that it does not. Certainly, the increases in CD4+ cells in 
our patient, mirrored by a rise in CD8+ cells suggest that even if repopulation of 
lymph nodes was not occuring, antigen-driven responses were. Other groups who 
have also transferred syngeneic lymphocytes to HIV-infected recipients have 
reported percentage increases in CD4+ lymphocytes but no serial data to estimate 
immediate kinetics are available (Lane, et al. 1990; Lane, et al. 1984). Our data 
indicate that a small rise in CD4+ count is detectable one hour after infusion (Table 
4) and that a concomitant rise in CD8+ cells is detectable at 2 hours. By 24 hours 
however, these counts were nearly back to baseline levels, suggesting a 
redistribution of cells to the lymphoid system. This redistribution of cells following 
adoptive transfer in mice has been documented in detail (Pape, et al. 1997). 
Unfortunately, our patient refused any further therapy or bloodwork beyond 45 
days and neither repeated infusions nor repeated lymphocyte counts could be done.
Virus loads
The virus load inexplicably decreased nearly one logfold one hour after cell infusion, 
followed by a rapid increase until it was approximately 65% of the baseline level at 
24 hours. It is difficult to explain this rapid decrease on the basis of CTL activity as 
the one hour time period is too short for any significant effector function (either 
killing or cytokine secretion) to occur. Similarly, the fall in virus concentration 
cannot be explained by a dilutional effect because of the relatively small volume of 
fluid (250 ml) infused. Ho et al (David Ho, personal communication) have reported
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that following bolus infusions of SFV into SFV-negative and SFV-positive macaques 
followed by animal sacrifice, less than 2% of the viral RNA can be accounted for 
following autopsy. He suggests that the virus may have undergone RNA 
degradation following infusion. Our case is a reverse of that situation, in that instead 
of infusing a bolus of virus to naive recipients, we are infusing a bolus of naive 
lymphocytes to an individual with high concentrations of circulating virus. The large 
numbers of cells infused may have "mopped up" free viral particles and taken them 
out of the peripheral circulation temporarily. Certainly, the kinetics of viral decrease 
correspond with the immediate rise and fall of lymphocyte counts. RNA 
degradation seems less likely since the virus loads returned to 2/3 of normal values 
within 24 hours.
TCR repertoire
The TCR V-beta repertoire of monozygotic twins discordant for HIV infection has 
been examined previously. In general, most groups report that TCR repertoires in 
HIV infected patients vary widely in contrast with those of their healthy 
monozygotic twins (Rebai, et al. 1994) while the TCR of identical, uninfected twins 
is relatively concordant and much closer than that of unrelated individuals (Hawes, 
et al. 1993, Loveridge, et al. 1991). We have examined the CD8+ repertoire of the 
uninfected and infected twin by flow cytometry and spectratyping. By flow 
cytometry, few expansions could be detected in any V-beta subset. This is surprising 
in light of the fact that the infected twin was harbouring numerous infectious and 
pathogenic organisms. But on closer examination, it may not be surprising. 
Depletion of repertoire is common in the late stages of HTV infection and an 
absolute lack of CD8 cells was certainly present before and 24 hours after transfer. 
Spectratyping may be expected to show TCR expansions not present by flow 
cytometry; however, because we did not amplify any normal cellular or 
housekeeping genes we do not have a standard with which to compare band 
intensity. Moreover, since the amount of V-beta mRNA transcript present 
intracellularly depends on the activation state of the cells (Paillard, et al. 1990) 
inaccuracies are expected to occur when quantifying expansions. Thus, we can only
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remark on whether the TCR V-beta families are perturbed or not perturbed and 
unlike repertoire determination using monoclonal antibodies, we cannot comment 
on the actual percentage of V-beta families present.
In agreement with other reports (Rebai, et al. 1994) we found that there was very 
little concordance in the CD8+ V-beta usage between the HIV-infected and 
uninfected twins. The uninfected twin had a full and normal spectratype repertoire 
with few band deletions (Figure 5). In contrast, the infected twin at the pre-infusion 
dmepoint had a limited repertoire (as shown by the numerous missing rungs in the 
ladders) and oligoclonal usage of V-beta subsets. At 24 hours after cell transfer, 
there was little change in the repertoire although there is suggestion of an additional 
clonal use in the V-beta 5.2 family. Expansions and limited repertoires which were 
present before infusion mostly remained 24 hours after infusion suggesting that 
there was not time for the infused cells to undergo significant replication or that the 
infused cells conformed to the ongoing clonal proliferations. However, four weeks 
after infusion PCR expansions were still largely maintained favouring the latter 
hypothesis - that ongoing clonal stimulation of infused cells was continuing. In one 
subset, Vb5.2 a more normal repertoire had been restored.
Another method for determining expansion is to measure band intensities. Using 
criteria established by others (Monteiro, et al. 1995), limited TCR usage was 
determined in selected V-beta subsets by defining an expansion as a single band 
present in spectratyping which accounts for greater than 50% of the total intensity 
of all bands. By these criteria, expansions were present in several different subsets at 
several different timepoints and generally correlate with a visual interpretation of the 
data (Figure 6). For instance, the VblB and Vb23 families had limited bands present 
on the spectratype gel and intensity analysis confirms expansions present at all three 
timepoints. However, an inherent flaw in the above argument is that it is difficult to 
distinguish between a clonal expansion and a loss of repertoire. Lanes exhibiting 
only one or two bands may indeed have undergone clonal expansion (supported by 
the similar basepair lengths of the amplified CD3 regions) or alternatively they may
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have undergone a deletion of clonal subsets leaving a restricted repertoire consisting 
of one or two bands. Because of our inability to quantify these PCR based results 
(as opposed to antibody staining and flow cytometry), it is not possible to distinguish 
between these two options. Moreover, because the paucity of cells obtained limited 
the amount of cDNA available for cloning and sequencing, it was not possible to 
determine whether these expansions were clonal or oligonclonal.
Imberti et al have postulated that the widespread deletions of V beta repertoire 
which they detected in a patient in the late stages of disease may be due to an HIV- 
encoded superantigen (Imberti, et al. 1991). This is not supported by studies which 
show random depletion of V-beta repertoire in patients with AIDS as compared to 
uninfected controls (Boldt Houle, et al. 1997)(Boyer, et al. 1993). In our patient, no 
absolute deletions were present despite a CD4+ count of less than 10/pl.
Exposing HIV-naive lymphocytes to replicating virus should in theory, mimic the 
situation of acute infection. Pantaleo et al have shown that large expansions of 
particular CD8+ V-beta families occur following acute infection with HIV (Pantaleo, 
et al. 1994). Of the six patients studied, maximal expansions of V beta subsets 
occurred at various timepoints after the onset of symptoms ranging from day 6 in 
one patient (where 18% of the PBMC analysed belonged to the V beta 4 family) to 
day 65 in another patient (where 12 % of the PBMC belonged to the V beta 8 
family). Acute infection with EBV also drives large antigen-driven clonal CD8+ 
expansions are present in acute infectious mononucleosis (Callan, et al. 1996). Thus, 
in our patient, exposure of donor lymphocytes to antigens derived from infection 
with M. avium-complex, H. simplex and Varicella zoster should have induced 
expansions in the relative V-beta families within the CD8+ subset as has been 
described for other infections (Islam, et al. 1996). Exceptionally high TCR V gene 
usage has been described in many infections as well as in healthy individuals making 
interpretation of T-cell clonal expansions difficult
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Restoration of repertoire may be a key event in the treatment of AIDS. Despite the 
rebound increase in CD4+ cell counts following use of antiretroviral therapy (in 
particular, therapy which uses at least one protease inhibitor) a number of early 
reports suggest that susceptibility to opportunistic infections remains high. In a series 
of 210 patients, 10 cases of acute CMV infection occurred within 10 weeks of 
initiating indinavir or ritonavir plus RT analogs (Poster Abstract 354, 4th 
Conference on Retroviruses and Opportunistic Infection). This occurred despite a 
greater than five-fold increase in CD4+ cell counts (from 32 +/- 27/pl to 150 +/- 
107/ul). Similarly, Michelet (Poster abstract 315, 4th Conference on Retroviruses 
and Opportunistic Infection) described 5 cases of CMV retinitis and 1 case of VZV 
retinitis among 80 patients shortly after they started on HAART. Jacobson et al 
reported 5 HIV-seropositive patients with baseline CD4+ counts of less than 85/pl 
who, following antiretroviral treatment, had a rise in CD4+ counts to greater 200/pl 
within 4-8 weeks, yet soon thereafter developed CMV retinitis (Jacobson, et aL 
1997). Using PCR spectratyping, the CD4+ TCR repertoires were examined before 
and after antiviral or antiviral plul IL-2 treatment (Connors, et al. 1997). Disruptions 
of the normal size patterns were observed in all 11 HIV-positive patients treated and 
these were associated with depletions in TCR-beta families. Abnormalities were most 
prevalent in patients with the lowest CD4+ T-cell counts. Both EL-2 and protease 
inhibitor therapies increased CD4+ counts but led to minor, if any changes, in 
disrupted TCR families. Thus the problem remains that naive T-cells are not being 
restored by anti-retroviral therapy. Paradoxically then, antiretroviral treatments may 
be most effective in patients prior to clinical disease when TCR repertoires may be 
relatively undisturbed. Thus the goal would be the early protection of T cell 
repertoire rather than the “unobtainable” restoration of T cell repertoire.
If highly active antiviral agents can decrease virus loads several fold and restore 
CD4+ and CD8+ lymphocyte subsets, then this is clearly the therapy of choice for 
those who have access to it. However, the limited data present suggests that the loss 
of TCR repertoire in late disease cannot be replaced by naive lymphocytes or stem 
cells. Restoration of global CD4+ counts is still unable to protect some individuals
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from opportunistic infections. Similarly, there are individuals with extremely low 
CD4+ counts who remain free from opportunistic infection. These individuals may 
represent the flip side of the repertoire analysis - that is, despite a low overall CD4+ 
count, the CD4+ lymphocytes which are present represent a large range of 
protective V-beta families. If this is the case, then treatment with highly active drugs 
should be instituted early in disease when the TCR-repertoires are relatively intact. 
For those individuals who have lost parts of their CD4+ or CD8+ repertoire, 
lymphocyte infusion may still be an option.
Outlook for lymphocyte transfer and BMT in AIDS
Ideally, the transfer of syngeneic lymphocytes would result in their engraftment and 
expansion. This is dependent on the ability of the host lymph nodes to permit 
expansion and this in turn, is probably dependent on pre-conditioning the patient 
with immunoablative therapy. In this respect, the previously published case reports 
on the use of BMT in patients with AIDS are extremely instructive. Although all 
these cases ultimately had undesirable outcomes, it is encouraging that in at least 
two patients, the virus appeared to be eradicated as demonstrated by reversal of 
serological status and negative PCR of autopsy tissues. In addition, both patients had 
marrow engraftment as was demonstrated by complete chimerism although this 
may simply reflect the fact that both patients were given conditioning therapy. 
Although rare case of spontaneous clearance of HTV have been reported (Burger, et 
al. 1985, Farzadegan, et al. 1988, Roques, et al. 1995) it seems unlikely that they 
would account for the disappearance of virus in this setting particularly since those 
cases usually involved patients with low virus loads and high CD4+ counts. Cursory 
examination of the data in Table 1 suggests that pre-transplantation conditioning 
may benefit patients undergoing transplantation. As was argued with adoptive 
therapy, prior destruction of myeloid and lymphoid cells by irradiation or 
chemotherapy appears to be necessary for optimal engraftment of marrow or 
expansion of lymphocytes either by creating "space" or more likely, by removing 
cells which interfere with engraftment and expansion (Bell and Shand 1975). 
Equally important however, is that the cells most affected by ablative therapy are
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the same cells which act as primary reservoirs for HTV. Thus, massive destruction of 
the hematological and immunological subsets of cells would result in a dramatic 
decrease in virus load. Such destruction may remove reservoirs of long-lived virus 
whose half-life of clearance by protease inhibitors is prolonged (Chun, et al. 1997, 
Perelson, et al. 1996). Ablative conditioning combined with highly active 
antiretroviral therapy may therefore result in near total elimination of the virus. This 
question was not answered by previous case reports because the majority occurred 
before the advent of protease inhibitors. Thus, sub-optimal anti-viral therapy 
(consisting of a single reverse transcriptase inhibitor) generally was used. In the case 
of the baboon transplant where despite graft rejection, the patient improved, triple 
therapy involving indinavir was used.
In the case of lymphocyte transfer, the quality of cells given to infected patients is 
also important. Levine et al have reported the growth of a population of CD4+ cells 
resistant to infection with NSI strains of HIV (Levine, et al. 1996). The combination 
of anti-CD3 and and-CD28 (and not PHA and IL-2) produces a complete down- 
regulation of CCR5 in the stimulated cell population (Carroll, et al. 1997). At the 
same time, CXCR4 expression increases significantly, and the cells are highly 
infeetable by T-eell-tropie virus. It is not known how long this effect will be 
maintained, but the previous studies of this group showed that the CD4+ cells 
activated in this way were resistant to HIV infection for several weeks. It would be 
interesting to transfer these in vitro resistant cells to patients with advanced 
immunodeficiency. However a number of known problems needs to be addressed. 
If a loss of the CD4+ TCR repertoire underlies the pathogenesis of immune 
deficiency, the expanded cells will need to express a full range of TCR V-beta 
families; the polyclonal nature of the CD3/CD28 stimulation eeU expansion has been 
shown to provide this. It will also be important to examine Fas expression on the 
expanded cells before infusion, to avoid their rapid elimination by apoptosis when 
they encounter HIV-infected cells with high Fas-L expression (Xu, et al. 1997). Cells 
generated by costimulation with anti-CD3/CD28 do however appear to be resistant 
to apoptosis (Levine, et al. 1996) and are also less susceptible in vitro to the adverse
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effects of gpl20 on proliferation and cytokine secretion (Faith, et al. 1996). It has 
also been observed that there is progressive down-regulation of CD28 during the 
course of HTV-infecdon - these cells may be refractory to the CD3/CD28 stimulation 
regime (Borthwick, et al. 1994). Most importantly however, cells expanded using 
the above protocol produce cells with upregulated CXCR4 expression. The impact 
of this cell phenotype on virus evolution is not known. However, homozygotes for 
the D32 mutation in CCR5 do not seem to be protected from rapid disease 
progression if unlucky enough to become infected (Bid, et al. 1997, O'Brien, et al 
1997, Theodorou, et al. 1997). In most patients with late-stage disease, SI variants 
predominate, so the rationale for transfer of activated cells with maximal CXCR4 
expression is poor. Ironically, it may be better to transfer cells to patients who have 
not yet developed AIDS, but in whom rising viral load and CD4+ cell decline 
foretell impending immunodeficiency. This approach still has potential, but until 
more information is available about the key mechanisms underlying CD4+ cell 
depletion, the potential consequences of cell transfer for virus evolution cannot be 
completely evaluated.
In summary, we have demonstrated that polyclonal expansions in CD4+ and CD8+ 
lymphoeytes can occur after syngeneic lymphocyte transfer. These expansions 
appear to be maximal around 28 days after infusion, in keeping with the timeframe 
present in stem cell transplantation in which bone marrow repopulates around 5 
weeks. Clinical correlation with the expanded lymphocytes is anecdotal although 
platelet counts returned to normal. This may have represented a restored 
lymphocyte response to his opportunistic pathogens but definitive proof is lacking.
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CHAPTER THREE
Adoptive Transfer Of Autologous HIV-Specific CTL To A Patient 
With A Low CD4 Count
Introduction
As discussed in some detail in the introduction to this thesis, infection with HIV 
produces a state of cellular immunodeficiency in the affected patient eventually 
resulting in the development of opportunistic infections and tumours, which are the 
hallmarks of AIDS (Rosenberg and Fauci 1990). Therapy of HTV infection currently 
relies on better drag protocols for preventing opportunistic diseases and the use of 
combined anti-retroviral drag therapy, also known as highly active antiretroviral 
therapy (HAART). Recently, the use of HAART has been shown to decrease virus 
loads by 1-3 log-fold, increase survival (Mellors, et al. 1996) and has raised the 
possibility of eventual elimination of the virus (Perelson, et al. 1997). More recent 
data however, suggests that residual pools of virus latently residing in lymphocytes 
and macrophages remain relatively resistant to therapy. Whether these virus infected 
cells are accessible to CTL is not known.
Several independent observations suggest that CTL are critical for the control of 
HTV infection. In other viral infections of humans and animal models, CTL appear to 
protect from disease. For instance, protection from CMV has been shown to reside 
in Class I restricted cells (Quinnan, et al. 1980, Rook, et al. 1984) and the adoptive 
transfer of CD8+ cells results in clearance of murine CMV infection (Reddehase, et 
al. 1987). Similarly, protection from influenza appears to be mediated by Class I 
restricted CD8+ lymphocytes (Lin and Askonas 1981).
Virus-specific CTL are present early in HTV infection and are temporally associated 
with decreases in the plasma virus load following primary infection (Borrow, et aL 
1994, Koup, et al. 1994).
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In addition, these early and vigorous responses have also been shown to drive the 
selection of viruses with mutations in the targeted epitopes, thereby providing 
convincing evidence for CTL-directed pressure (Borrow, et al. 1996, Price, et al. 
1997). During the asymptomatic phase of infection, HIV-specific CTL are present at 
high ffequencies(Langlade-Demoyen, et al. 1988, Nixon, et al. 1988, Riviere, et aL 
1989, Walker, et al. 1987) and a decline in CTL activity is associated with transition 
to AIDS and increasing morbidity (Klein, et al. 1995). It has also been shown that 
patients with higher frequencies of Env-specific memory CTL had a statistically 
significant median level of plasma HIV RNA about 1/3 that of patients with lower 
frequencies (Musey, et al. 1997). CTL responses have also been detected in infants 
and sex workers who had been exposed to HTV but who remained free of the virus, 
suggesting that CTL may play a role in preventing infection in some patients 
(Rowland-Jones, et al. 1993, Rowland-Jones, et al. 1995) and in a closely related 
animal model, the inhibition of CTL by the infusion of CD8-blocking antibodies was 
shown to result in marked elevations of simian immunodeficiency virus (SIV) in the 
plasma and lymph nodes of infected macaques (Matano, et al. 1998). More recently, 
a strong inverse correlation between numbers of circulating HIV-specific CTL and 
plasma viral load has been demonstrated (Ogg, et al. 1998). Taken together, these 
and other reports are consistent with the view that CTL responses are an integral 
part of virus control (Rowland-Jones, et al. 1997).
Adoptive cell transfer has been well-documented in animal models (reviewed in 
Greenberg 1991, Riddell and Greenberg 1995). Cell transfers in cancer patients 
have consisted of two effector populations. The first are lymphokine activated killer 
(LAK) cells which are generated by short term culture of peripheral blood 
lymphocytes in the presence of high concentrations of IL-2. These cells lyse 
transformed target cells and have minimal activity against normal tissues (Grimm, et
al. 1982, Sondel, et al. 1986). Up to 10H LAK cells, generated in vitro, have been 
given to patients in a single intravenous dose. Patients experienced only minor
73
symptoms and no pulmonary compromise demonstrating the safety of these 
infusions (Rosenberg, et al. 1987, Rosenberg, et al. 1985)
The second population are in vitro expanded lymphocytes derived from tumours. 
Such tumour-infiltrating lymphocytes (TIL) havae been shown, in a murine model 
of adoptive transfer, to be 50-100 times more effective than LAK cells in 
eradicating micrometastases (Rosenberg, et al. 1986). TIL lines can be expanded to
lOH cells over a period of 3-8 weeks and some lines possess lytic activity which is 
restricted to autologous but not allogeneic tumour target cells while others, like 
LAK, lyse autologous and allogeneic cells equally well (Itoh, et al. 1986, Kradin, et
al. 1987, Topalian, et al. 1987). Adoptive transfer of 5 x 10*0 TIL cells along with 
IL-2 has resulted in toxicides which were attributable to IL-2 alone (Rosenberg, et 
al. 1988, Topalian, et aL 1988). Indium-111 labelling of TILs showed initial 
localization in the lungs, liver and spleen two hours after infusion and localization at 
sites of metastatic tumour by 24 hours (Fisher, et al. 1989).
And as described in the introduction, adoptive cell transfer has been successfully 
attempted using CMV and EBV-specific CTL. However, in contrast to adoptive cell 
transfer studies in patients at risk of CMV or with EBV infection, there are a 
number of considerations unique to adoptive cell transfer for HTV infection. Because 
many, if not most of the host cell targets of HIV are part of the immune system, 
CTL recognition and destruction of infected cells may result in destruction of 
macrophages and also CD4+ cells. This raises the possibility that massive CTL 
targeting of infected CD4+ cells may drastically reduce the CD4+ population. 
Nonetheless, the underlying assumption is that these CD4+ cells are infected, 
dysfunctional and productive of virus. Thus, destruction could only be beneficial.
Destruction of CD4 cells also results in the release of infectious virions, though 
possibly less than if viral-mediated lysis were able to progress naturally. The half-life 
of infected target cells subject to CTL-mediated lysis in vitro (at effector:target ratios
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which are present in vivo) has been calculated to be around 0.7 days and thus in 
theory, HIV-specific CTL are present in sufficient numbers and act with sufficient 
kinetics to contribute to the lysis of infected cells and a decrease in the production of 
infectious virus (Klenerman, et al). Using these calculations, if the CTL to target 
ratio could be raised several-fold by adoptive transfer of HIV-specific clones, 
reduction of virus may be significantly affected, aside from the effects of disrupting 
infected cells prior to virus maturation.
Another consideration is that the survival and effector function of CTL may be 
highly dependent on CD4 cells - the very cells which are diminished in late HIV 
infections and AIDS. For instance, in mice with a null mutation of the CD4 gene, 
anti-viral CTL activity was diminished (Battegay, et al. 1994). Thus, in the setting of 
a low CD4+ count, adoptively transferred CTL may lack both optimal effector 
function and the ability to survive and expand efficiently.
Transfer of large numbers of specific CTL may also drive escape mutation of the 
virus. This was most clearly demonstrated by Koenig et al when they transferred
IQlO CTL specific for an A3-restricted nef epitope (Koenig, et al. 1995). Prior to 
transfer, sequencing of the patient’s virus revealed wild-type nef sequences; 
however, following two courses of nef-specific cell infusions, the majority of the 
virus population in the patient had mutations in and around the nef epitope.
We have examined the safety, feasibility and utility of CTL transfer to two HIV- 
infected patients. The data for the first patient (008) are presented in this chapter 
and the data for second patient (868) are presented in the next chapter. These two 
patients differ in a number of respects as outlined in Table 7. Perhaps most 
importantly, Patient 008 has a low virus load and (paradoxically) a low CD4 count 
while Patient 868 had a relatively high virus load and a high CD4 count. The 
importance of these observations will be discussed later.
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Table 7. Clinical characteristics of adoptive transfer patients 008 and 868
Patient 008 Patient 868
Age 34 34
Years infected 14 7
CD4 cells/pl at time of infusion 20 600
RNA copies/ml at time of infusion 30000 60000
Antiretroviral therapy None AZT, DDI
Opportunistic diseases None HSV, PCP
Two patients with AIDS, 008 and 868, were adoptively transferred with 
Hlv-specmc CTL over a period of two years. The patients differed with 
respect to CD4 cell count, viral load and anti-retroviral medications 
herpes simplex virus (HSV),azidothymidine (AZT), didanosine CDDD 
pneumocystis carinii (PCP).
Methods
Obtaining peripheral blood mononuclear cells
Peripheral venous blood was obtained through a #21 gauge butterfly needle into a 
50 ml syringe. The blood was placed into sterile 50 ml conical tubes containing 50 
pi of preservative-free heparin sulfate (Leo Laboratories, 1000 units/ml). Blood was 
diluted 1:1 with sterile RPMI and gently layered onto a density gradient 
(Lymphoprep) at a volume ratio of 2:1 blood to frcoll in either 25 ml universal tubes 
or 50 ml conical tubes. The tubes were centrifuged at 400 x g for 30 minutes at 
room temperature with the brake off. The buffy coat interface containing 
mononuclear cells was aspirated with a sterile transfer pipette, washed with sterile 
RPMI and centrifuged for 10 minutes at 800 x g. The cell pellet resuspended and 
washed again with RPMI and centrifuged a further 10 minutes at 400 x g. The cells 
were resuspended in RPMI containing either 10% fetal calf serum or 10% human 
serum, penicillin and streptomycin and glutamine (referred to as R10 or HSR10). 
The average yield from a healthy volunteer was 1 million PBMC per 1 ml of whole 
blood. Concentrated buffy coats obtained by leukapheresis were occasionally bought 
from the Oxford Transfusion Service. These yielded 3-5 million PBMC per ml of 
buffy coat.
Establishing B-cell lines (lymphoblastoid cell lines. LCD
A  minimum of two and a maximum of ten million PBMC were pelleted in a 
universal tube and resuspended in a 1 ml aliquot of supernatant obtained from an 
EBV-producing marmoset cell-line B958 and incubated for 1 hour at 37 °C in an 
atmosphere of 5% C02. The PBMC were then resuspended in 9 mis of RPMI 
containing 15% fetal calf serum, penicillin and streptomycin and glutamine and 1 
pg/ml cyclosporin A  (for suppression of T-cell growth). The suspension was placed 
in a 50 ml tissue culture flask and incubated at 37 °C in an atmosphere of 5% C02. 
B-cell lines took from 2 weeks to 6 weeks to become fully established. R10 medium 
was added to the cells periodically. When B-cell lines were established, they were 
grown in 200 ml flasks in a volume of approximately 20 mis.
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Cell irradiation
In order to prevent ongoing mitosis and expansion of feeder cells, both PBMC and 
BCL were irradiated with a total of 3000-5000 rads in a Cesium gamma-irradiator 
(Atomic Energy Commission of Canada).
HLAjypjng
HLA typing was done using an amplification refractory mutation specific (ARMS) 
method developed by Bunce et al (Bunce, et al. 1995). Briefly, genomic DNA was 
extracted using a Puregene DNA kit (Centra, Madison, Wisconsin). Genomic DNA 
was used as a template in the polymerase chain reaction (PCR) amplification of the 
HLA region (exons and introns) using allele-specific primers and controls. 
Amplification products were separated by agarose gel electrophoresis and 
photographed under ultraviolet light Lanes containing positive bands were noted 
and interpreted according to a key in order to determine the HLA Class I 
haplotype. Separate HLA Class I subtyping reactions were performed as required.
Production of CTL lines
CTL lines were either produced through bulk culture in which autologous HIV 
infected lymphocytes served to stimulate CTL or through peptide-specific 
stimulation. A pellet consisting of two to five million PBMC was incubated with 100 
jliM peptide in a volume of 100 pi for 2 hours at 37 °C. The pellet was then 
resuspended in R10 and aliquotted into a 24 well plate at 2 million cells per well. IL- 
2 (25 cetus units/ml) or lymphocult-T (final concentration 10%, Biotest AG, 
Dreieich, Germany) was added to the cells three days later.
Bulk cultures were produced by resuspending approximately 5 million PBMC in 5 
mis of R10 in a 50 ml flask overnight at 37 °C. Approximately 1 million cells were 
resuspended in 2 mis of R10 and 10 pi of phytohemagglutinin (PHA, Murex) in a 
single well of a 24 well plate (roughly 5 pg/ml). This has the effect of activating T 
lymphocytes, thus stimulating virus production in the infected cells. After 16 hours,
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the PHA stimulated cells were washed once in sterile RPMI and added to the flask 
containing unstimulated PBMC. An aliquot of PHA blasts was frozen for PCR and 
virus sequencing.
Production of Clones
CTL clones were derived from CTL lines by a method of limiting dilution. Cloning 
mix consisting (per 10 mis of RIO) of 10 million irradiated PBMC (from three or 
more different donors), 1 million irradiated, autologous B-cell lines pulsed with 1 - 
100 uM peptide and PHA (1:1000 dilution) was added to CTL such that when 
plating into a 96 well flat-bottom plate at 100 pl/well the average number of CTL 
per well was 0.3, 3 or 30. Usually, two plates at each concentration were made. 
Lymphocult-T was added to each well at day 3 after stimulation (final concentration 
10%) and the plates were left until day 14 at which time they were examined under 
an inverted microscope for evidence of T-cell growth. Positive wells were marked 
and expanded into 24 well plates (with cloning mix) a further 10 days and tested by 
cytotoxicity assay. In general, cells which grew rapidly did not lyse target cells as 
well as cells which grew slowly. Thus, the cloning plates were subjected to a second 
screen 20 days after stimulation and positive wells were again marked, expanded 
and tested. In addition, in accordance with a recent report (Alexander-Miller, et aL 
1996), cloning with the use of lower concentrations of peptide (1 foM or less 
compared to 100 pM) often yielded clones which more efficiently lysed target cells.
Freezing and thawing cells
Two to twenty million cells were resuspended in 2 mis of freezing medium 
containing either 90% FCS (Sigma) and 10% dimethyl sulfoxide (DMSO) or 70% 
RPMI, 20% human serum and 10% DMS) and placed in a 2 ml freezing vial 
(Nunc). The vial was either placed on ice for 30 minutes or placed into a 4 °C 
isopropanol controlled rate freezing container, then placed in a -70 °C freezer 
overnight. After 16 hours the vials were transferred to liquid nitrogen tanks. Cells 
were thawed rapidly by placing frozen cryovials into a 37°C incubator and
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resuspending the cells in cold RIO. The cells were washed twice in RIO and plated 
at 2 x 106 cells/well of a 24 well plate with IL-2.
Peptide svthesis and HPLC
Peptides were synthesized by Karl McIntyre in the Institute of Molecular Medicine 
or purchased from Research Genetics (Alabama). In-house synthesized peptides 
were freeze dried and assayed for purity by high performance liquid 
chromatography (HPLC). Stock peptides were dissolved in DMSO to a 
concentration of 1 mg/ml and diluted into sterile RPMI for subsequent use.
CTL cytotoxicity assay
Effector cells were washed once, resuspended in RIO, counted and made to a 
concentration of 1 million cells per ml. One hundred thousand cells (100 pi) of this 
was placed into a U-well of a 96 well plate. Target cells were usually autologous 
transformed B-cell lines. B-cells were pelleted by centrifugation and resuspended in 
approximately 300 pCi of Cr-51 for 45 minutes at 37 °C. The cells were then 
washed twice with RPMI, the pellet was resuspended in 100 pi of peptide at the 
relevant concentration and incubated at 37 °C for 1 - 2 hours. The cells were 
washed twice in RPMI and then resuspended in 1 ml of R10 and counted in a 
hemacytometer. The cells were made to a concentration of 100,000 per ml and 
placed into a U-well at a concentration of 5000 cells per well. Minimum lysis 
consisted of wells in which the target cells were in medium alone. Maximum lysis 
consisted of wells in which the target cells were lysed with 100 pi of 5% triton-X. 
Target and effector cells were incubated together for 4-5 hours at 37 °C and 20 pi 
of supernatant was harvested from each well onto a fibre mat. The mat was dried in 
a microwave oven and placed in a plastic bag with 10 mis of scintillation fluid and 
counted on a beta-plate counter. Lysis was calculated according to the formula:
mean cpm target/effector well - mean cpm minimum lysis well 
mean cpm maximum lysis well - mean cpm minimum lysis well
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Preparing human serum
Human serum was prepared from volunteers who fasted 16 hours prior to 
phlebotomy as lipids appear to interfere with optimal CTL growth (K. Watanabe, 
Fred Hutchison Research Center, personal communication). Approximately 200 mis 
of blood was drawn serially into 50 ml syringes and placed in sterile 50 ml conical 
tubes containing no heparin. The tubes were left at room temperature for six to 
eight hours and then centrifuged at 2500 RPM in a Beckman centrifuge for 20 
minutes at room temperature. The serum was drawn through a sterile plastic straw 
(Kwill) into a 50 ml syringe and pooled into a sterile 50 ml tube. The tubes were 
centrifuged for a further 10 minutes and the serum was decanted from the red 
blood cell pellet and placed in 65 ml aliquots. One ml aliquots of serum were saved 
for HTV, HBV and HCV serology. The 65 ml aliquots were heat inactivated in a 58 
0C waterbath for 1 hour and frozen at -20 °C.
Large scale expansion of CTL for infusion
Large scale expansion of CTL was based on the methods of Riddell and Greenberg 
(Riddell, et al. 1992, Walter, et al. 1995). Briefly, CTL were grown upright in T25 or 
T75 tissue culture flasks. Each flask contained the T-cell clone, irradiated mixed 
allogeneic PBMC and mixed allogeneic irradiated LCL which acted as feeder cells. 
TCR stimulation was provided by monoclonal anti-CD3 (OKT3) and HSR 10 was 
the culture medium. The details of additions are in Table 8 and a more extensive 
discussion of CTL expansion follows.
Large scale expansion of CTL clones or oligoclonal lines is technically 
straightforward but not always successful. To a large extent, the nature of the clone, 
which is to be expanded, is important. We and other investigators have found that 
clones which have received repeated TCR stimulation do not expand with the 
efficiency of recently cloned cells (Dr. S. Riddell, personal communication). Thus, 
ideally, the CTL should undergo one large scale expansion following their initial 
cloning, and aliquots of these cells may then be cryopreserved for future expansions.
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Table 8: In vitro CTL expansion protocol
T25 flask T75 flask
T-cell clone 5 x 104 -1  x 105 2 x 105 -5 x 105
Irradiated allogeneic PBMC 25 x 106 75 x 106
Irradiated allogeneic LCL 5x106 15 x 106
Anti-CD3 (OKT3) 30ng/ml 30ng/ml
RPMI with 10% Human Serum
Total Volume 25-30 mis 50-60 mis
CTL were expanded in number in vitro prior to adoptive transfer. CTL 
clones were cultured in either T25 or T75 flasks for a period of 14 days 
using irradiated lymphoblastoid cell lines (LCL) and peripheral blood 
mononuclear cells (PBMC) as antigen presenting and feeder cells, in 
medium supplemented with human serum and IL-2. Further details are 
described in the text.
In addition, CTL which are derived from HIV-infected patients whose CD4 cell 
counts are below 200/pl do not appear to grow as vigorously. In general, cells grow 
more succesfully in smaller flasks (eg. T25 (50 ml) flasks vs. T200 (600 ml) flasks). 
However, the use of the T25 flasks requires the manipulation of numerous flasks 
increasing both the labour involved and the chance of bacterial or fungal 
contamination. Thus, in practice, the use of T75 (200 ml) flasks represents an 
acceptable balance between cell growth and manual labour. Large numbers of LCL 
and PBMC are required for large scale expansion and these may be prepared 
beforehand and frozen. PBMC are best generated by ficoll separation of 
leukapheresis-prepared buffy coats which may be obtained from the local blood 
authority.
Equipment and reagents required for large scale expansion
• CTL clone (2 million cells)
• anti-CD3 (OKT3, Orthoclone) stock 1 pg/ml
• irradiated, syngeneic or allogeneic LCL (150 million cells)
• irradiated, allogeneic PBMC (750 million cells)
• 1 x T200 tissue culture flask
• 10 x T75 tissue culture flasks (Costar)
• Plastic Universal tubes (25 mis) or conical tubes (50 mis)
• hemocytometer
• RPMI 1640 medium supplemented with glutalmine, penicillin, 
streptomycin and 10% human or fetal calf serum
Preparation of the cells and reagents
i) In a T200 sterile flask, combine CTL clone, PBMC and LCL in 100 mis of 
R10.
ii) Add 15 pg of anti-CD3 (final concentration = 30 ng/ml) and bring volume 
up to 500 mis with R10.
3. Distribute cell mixture to 10 x T75 flasks, 50 mis per flask.
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4. Incubate flasks upright at 37 °C, 5% C02 overnight.
i) Add IL-2 (human recombinant 25 ceturs units/ml) to flasks the next day.
ii) Five days after initial setup, harvest cells from all flasks, wash once with 
RPMI and resuspend in R10/LL-2 at 50 mis per flask x 10 flasks.
iii) Eight days after setup, resuspend the cells in a representative flask and 
count. If the cells concentration is > 2 x 106 per ml, split 1 flask to two 
flasks.
8. Test cells for CTL activity at 12-14 days.
Anchored PCR and TCR cloning
The anchored PCR method has been previously described (Loh, et al. 1989, Moss, 
et al. 1995). An overview is presented in Figure 7.
Figure 7: Anchored PCR method overview
CTL clonal cDNA was produced from oligo-dT primed RNA. A poly-G tail was 
added with terminal transferase and PCR to amplify the CDR3 region was primed 
by oligonucleotides complementary to the constant regions of V-beta and V-alpha 
and the poly-G tail. The amplified product was purified from the gel and cloned into 
phagescript vector and the nucleotide sequence was determined by 
dideoxynucleodde sequencing.
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Figure 7: Anchored PCR Method 
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RNA was prepared from 1-5 million CTL using RNAzol or TRI (Sigma). Oligo dT 
(Collaborative Research) primed cDNA was synthesized with MMLV reverse 
transcriptase. The cDNA product was ethanol precipitated three times and then a 
poly G tail was added to the 5' end using terminal transferase. The poly G cDNA 
was extracted with phenol/chloroform and used in a template in a PCR reaction. 
The poly G tail serves as an anchor a poly C primer and a constant alpha or beta 
region primer. Primers were as follows:
Poly-C anchor 5’ gca ttc age tgc ggc ege (c)l4 3’ (includes Notl site)
A Sal AMP (a) 5’ tga ccg cag teg aca gac ttg tea ctg gat 13’
Cb AMP Sal (b) 5’ ata ctg gag teg acg gag ate tct get tct gat g 3’
The poly-C anchor contains a 5' Not 1 site and the Calpha and Cbeta anchors each 
contain a 5' Sal site. The cycling parameters were:
1 cycle 94° for 4 minutes
5 cycles 94° for 1 minute
65° for 1 minute 
72° for 2 minutes
35 cycles 94° for 1 minute 
58° for 1 minute 
72° for 2 minutes
PCR products were purified through a Wizard Prep mini-column (Promega) and a 
small aliquot was run on a 1.5% agaroseATBE gel. A 600 base pair product 
corresponded to the TCR PCR product.
The PCR product was then digested at 37 °C overnight with Not 1 and Sal. The 
digested product was separated on a 6% acrylamide gel and the relevant band was
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identified by ethidium bromide staining, excised and eluted overnight in acrylamide 
elution buffer. The DNA was ethanol precipitated and a ligation reaction consisting 
of insert DNA, Phagescript SK vector and T4 ligase (Boehringer) was performed. 
Ligated vector was transformed into competent XL1-MRF E. coli with blue-white 
selection. White colonies containing insert were grown in XL1 bacteria until 
OD600=0.5 and single-stranded phage DNA was precipitated from the 
supernatants. Single-stranded DNA was used as a template in dideoxy nucleotide 
sequencing (USB Sequenase 2.0).
Flow cytometry
Cells were pelleted in a universal tube (800 x g for 5 minutes) and resuspended in 
PBS/BSA at a concentration of 3-5 million/ml. Aliquots of 100 pi were placed in the 
round bottom wells of 96 well plates according to the number of staining conditions. 
The plate(s) was spun in a centrifuge for 5 minutes, the supernatant "flicked" out 
and the plate subjected to vortexing. The cells were then suspended in 
PBS/1 %BSA/1% human seram/1 % mouse serum and stained with the relevant 
antibodies for 30 minutes on ice. For double or triple staining the cells were washed 
twice and pelleted between labellings. Cells were resuspended in 400 pi of PBS/1 % 
FCS/1% formaldehyde and analyzed on a Beeton-Diekinson FACSean using 
Cellquest software.
Sterility Testing
Briefly, one ml of a given cell culture was placed in a sterile tube and centrifuged at 
1000 x g for 10 minutes. The supernatant was decanted to a separate sterile tube. 
Both tubes were submitted to the microbiology lab for bacterial and fungal culture 
using a blood culture protocol. Aliquots of cells were also tested for mycoplasma 
and pelleted cells were submitted to virology for PCR testing of HBV, HBV and 
EBV. A more detailed discussion of safety issues follows.
The two paramount considerations in transferring cultured cells to patients are the 
sterility of the preparation and the absence of transformed cells. Because the
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population receiving adoptive cell therapy is often immunosuppressed, any 
transferred organisms may produce serious infections. The cells and growth medium 
must be periodically assayed for bacterial, viral and fungal contamination. However, 
because CTL may be infected at anytime up to the moment of transfer and because 
the culture of fastidious organisms may require days to weeks of incubation, it is 
usually necessary to infuse cells prior to complete culture results. Hence, meticulous 
handling of cells is an absolute requirement. One way of avoiding this problem is to 
cryopreserve cells at their peak of lytic activity and thaw them just prior to transfer, 
when the microbiological results have been finalized. However, there is often a 
reduction in cytotoxic activity as well as a loss of absolute cell numbers in 
lymphocytes which have been frozen. Organisms likely to contaminate cell cultures 
include my coplasmas, yeast and other fiingi. In our practice, we screen cells for 
contamination three days before and on the day of infusion by testing aliquots of 
cells for mycoplasma and sending samples to the clinical microbiology laboratory 
for cultivation using a blood culture protocol. While not ensuring that samples are 
absolutely sterile at the time of infusion, the latter samples allow us retrospective 
diagnosis of any bloodbome infection. In addition, as mentioned in above, it is 
necessary to screen the human serum used in cell culture media for bloodbome 
viruses such as HTV, HBV and HCV.
Most protocols for lymphocyte expansion utilize EBV transformed B cells (LCLs) 
as either antigen presenting cells and/or a source of costimulatory molecules. These 
cells must be thoroughly irradiated prior to use to prevent the escape of any 
transformed cell (4000-8000 rads). One method of testing whether the B cells have 
been sufficiently irradiated is to maintain an aliquot in appropriate medium and 
observe the cells for outgrowth. Other investigators have also taken the additional 
precaution of growing LCL in acyclovir-containing media thus preventing the 
formation of late lytic cycle infectious EBV particles (Hague, et al. 1998).
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Vims loads
HTV RNA plasma titre was determined using the HIV Amplicor kit from Roche. 
Briefly, RT-PCR was performed on 200 pi of EDTA plasma and controls. PCR 
product was purified and applied to 96 well microtitre plates coated with 
complementary oligonucleotide-biotin complex. The plates were washed and 
product was detected with a streptavidin-HRP colour indicator. A standard curve of 
RNA copies per ml was constructed from the control RNA extractions and patient 
samples were plotted.
Patient Consent
Ethical approval was obtained from Central Oxford Regional Ethics Committee 
(COREC) and informed consent from the patient.
Results
Patient 008
Patient 008 was a 34 year old white male hemophiliac who contracted HTV from 
contaminated Factor Vm concentrate infusions approximately 14 years prior to this 
study. At the time that we first began studying him, his CD4 count was > 500/pl 
and he was receiving no medications. At the time when this adoptive transfer study 
was being planned, his CD4 count had declined to approximately lOO/pl and at the 
actual time of infusion, the CD4 count was 20/pl. At no time during the infusions 
did he develop any opportunistic infections or receive any anti-retroviral medication. 
His declining CD4 lymphocyte count is shown in Figure 8.
Importantly, Patient 008 seemed to have lost over time his CTL responses to Pol 
and to Gag (Figure 9 and personal communication, Sarah Rowland-Jones). Thus, 
there appeared to be an opportunity to restore his CTL responses by adoptive 
transfer of CTL.
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Figure 8: Patient 008 CD4 count
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CD4 cell counts from Patient 008 for an 8 year period preceding adoptive 
transfer of CTL. Counts are expressed as cells/pi.
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Figure 9: Patient 008 Historical CTL Responses to Gag & Pol
Declining CTL response over time 
from donor 008 to the A2-restricted
polpeptide
1990 1991 1992 1993 1994
PBMC from Patient 008 were restimulated with Pol 
peptide (ILKEPVHGV) at the indicated timepoints and 
tested for CTL activity for a 4 year period preceding 
adoptive transfer.
HIV-specific CTL clones derived from Patient 008
Three CTL clones, derived from Patient 008 in 1991 by Stephen Me Adam, were 
thawed, cultured and tested for CTL activity (Table 9, Clones 18,20,28). Clone 18 
did not grow well initially and the other two clones were considered for expansion 
and infusion. Clone 28 which recognizes an HLA ^-restricted nonamer derived 
from Gag p24-13 (GEIYKRWII) was an excellent killer cell line with 60-80% 
specific lysis at a 2:1 effector-target ratio (Figure 10). In contrast, Clone 20 which 
recognizes an A201-restricted nonamer derived from the pol product of HIV 
(ILKEPVHGV) had a lower level of specific lysis (Figure 10). Both clones also 
recognized HIV variants (GDIYKRWQ and DLKEPVHEV respectively) which had 
previously been sequenced from the patient.
Table 9: HIV-specific CTL clones derived from Patient 008
Clone HLA Epitope 1 2 3 4 5 6 7 8 9
18 B8 pl7 G G K K K/R Y K L
20 A2 pol I L K E P V H G/E V
28 B8 p24 G E/D I Y K R W I I
41 B8 p24 G E/D I Y K R W I I
CTL clones previously derived from Patient 008 recognized the indicated epitopes 
from Pol, Gag pl7 and Gag p24 restricted by HLA A201, B801 and B801 
respectively. These clones were tested for CTL activity before cryopreservation. The 
original nomenclature for the clones is retained in the text. Clones also recognized 
the indicated variant peptides sequenced from Patient 008.
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Figure 10: Activity of the HIV-specific CTL clones from Patient 008
The CTL clones described in Figure 9 (Clones 20 and 28) were thawed, recultured 
and tested in duplicate for CTL activity against autologous target LCL coated with 
1 pM of indicated peptide at different effectontarget ratios. Clone 20 (HLA A2 Pol 
restricted) is represented by dark squares while Clone 28 (HLA B8 Gag restricted) 
is represented by dark circles.
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Figure 10: HIV-specific CTL clones from Patient 008
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Anchored PCR for V-alpha and V-beta clone sequences 
Both clones were subjected to anchored PCR in order to:
1. confirm their clonality
2. determine their V-beta family
3. identify their specific VDJ/CDR3 sequences
The V-alpha and V-beta CDR3 sequences for both clones are shown in Figure 11. 
Clone 20 was determined to be Vb2.1/Jbl.2, Val7/Ja9.16 and Clone 28 was 
Vbl6.1/Jb2.2, Val 1/Jal3.2/Va7/Jal5.3. The two V-alpha sequences for clone 28 
reflect the fact that although allelic exclusion restricts a lymphocyte to expressing 
only a single V-beta recombinant, two V-alpha chains both of which may pair with 
the V-beta chain, are permissible. At least 16 cDNA-transformed clones were 
sequenced for each CTL line and these were the only in-frame sequences obtained.
. Flow cytometry of clones 
The CTL clones were then subjected to flow cytometry in order to further 
characterize their phenotype. The primary FACS data are shown in Figures 12 and 
13. Clone 28 was the expected phenotype, with surface expression of CD8 and V- 
beta 16 but not CD4 or V-beta 2. In contrast. Clone 20 was unexpectedly mixed, 
with 85% of the line expressing CD4 (and 15% expressing CD8) and 80% of the 
line expressing V-beta 2.1. This phenotype is consistent with a oligoclonal line 
consisting of both a CD4 and CD8 clone.
Magnetic bead separation of Clone 20
Clone 20 (HLA A2-pol specific) was separated into CD4 and CD8 fractions using 
monoclonal antibodies bound to magnetic beads. The separated fractions were then 
tested for CTL activity (Figure 14). Clone 20 (before fractionation) had a specific 
lysis of 25% while the CD4 and CD8 fractions respectively had specific lysis of 9% 
and 45%. Thus the CTL activity of Clone 20 resides in the CD4-CD8+ fraction of 
the cells. These data serve to explain some of the phenomena observed:
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Figure 13: TCR Phenotype of Patient 008 Clones 28 and 20
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Immunophenotype of Clone 20 (A2 Pol), top two panels and Clone 28 (B8 
Gag p24) bottom two panels. FL1 refers to staining with either V-beta 16 or 
V-beta 2.1 followed by anti-mouse Ig FTTC.
1. Clone 20 did not lyse cells as efficiently as normal clones.
2. Anchored PCR detected only a single V-beta CDR3 sequence.
Efforts to clone the CDS expressing clone from this oligoclonal line yielded two 
separate clones, neither of which could be cultured efficiently.
Figure 14: CTL activity of CD4+ fraction of Clone 20
Clone 20 was fractionated using magnetic beads conjugated with antibodies to CD4 
or CDS and each fraction was tested for CTL activity against autologous LCL 
coated with 1 pM of Pol peptide. CL20 is unfractionated Clone 20. CL20-CD4 
refers to the CD4+ fraction of Clone 20 while CL2O-CD4 refers to the d e ­
traction. CL20-gag refers to Clone 20 tested against autologous LCL coated with a 
control Gag peptide.
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First Infusion
Table 10 summarises the clones and cell numbers transferred into Patient 008. 
Clone 28 was expanded for the first infusion. Two weeks prior to infusion, the cells 
were cultured according to the protocol of Riddell et al. Aliquots of cells and 
supernatant were obtained on infusion day for microbiological and virological 
testing. Because of the theoretical risk of infusing irradiated autologous B cells, anti- 
EBV serology was obtained and the EBV IgG was positive. (And-EBV CTL lines 
could not be made from Patient 008 PBMC, Figure 15).
The cells were tested on Day 13 for CTL activity (Figure 16). Twenty-five million 
cells of Clone 28 were obtained for the first infusion. These were washed three times 
in PBS, resuspended in 250 ml of normal saline and transported to the ward for 
infusion. The cells were infused via a 21 gauge butterfly in the median vein of the 
antecubital fossa over a period of 15 minutes. Venous blood was obtained at various 
timepoints following infusion for cell counts, flow cytometry, virus loads and CTL 
assays.
Table 11 summarises the hematological and virological assays following the first 
infusion. The optimal dmepoint for detecting any increases in leucocyte counts or in 
CD4+ or CD8+ cells would be shortly after infusion, but at one hour post-infusion, 
there was no significant rise in these cell numbers. Similarly, there were no 
significant decreases or increases in viral load followed up to one week post-infusion. 
In theory, the largest drop in virus load due to the cytotoxic activity of infused cells 
should occur mostly within the first 12 hours after infusion.
Lymphocytes obtained from the patient before and after infusion were also tested 
for cytotoxic activity against autologous transformed B lymphocyte cell lines 
exogenously loaded with relevant peptide. Patient lymphocytes were either tested 
immediately ex vivo (fresh CTL assay), an assay in which the PBMC are incubated 
directly with target cells or restimulated with peptide and EL-2 in an attempt to 
increase the precursor frequency of HIV-specific CTL, then assayed (cultured or
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Figure 15: Patient 008 EBV CTL
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Figure 15 Patient 008 EBV-specific CTL activity
PBMC from Patient 008 were restimulated and cultured with the 
indicated peptide epitopes derived from Epstein-Barr virus (EBV) 
and tested for CTL activity against autologous LCL coated with the 
relevant peptide.
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Figure 16: Patient 008 Clone 28
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Figure 16: Patient 008 Clone 28 CTL activity pre-first infusion
The cytotoxicity of Clone 28 was tested on the day of infusion. 
Target cells were autologous LCL coated with 1 pM of HLA-B8 
restricted p24 peptide at the indicated effectontarget ratios.
Table 11: Hematological and virological laboratory markers before and 
after the adoptive transfer HIV-specific CTL.
a. First Infusion 0 -i-lhr +4h +20h +7d
WBC 2000 1500
CD3 . 640 (68) 600 (65)
CD4 30 (4) 20 (4)
CD8 630 (63) 600 (60)
Virus (copies/ml) 31,000 20,000 35,000 25,000 51,000
b: Second Infusion 0 +lhr +4h +20h +7d
WBC 1700 2000
CD3 410 (63) 490 (68)
CD4 30 20
CD8 380 450
Vbl6 1.80% 2.40%
Vbl7 5.40% 5.40%
Virus (copies/ml) 56,000 49,500 49,000 66,000 59,000
c. Third Infusion 0 +2hr +6d +18d
WBC 1700 2100
CD3 310 (64) 420 (67)
CD4 10 (3) 20 (3)
CD8 290(60) 400 (63)
Virus (copies/ml) 49,000 41,000 65,000 84,000
Blood samples obtained from Patient 008 at each of the indicated timepoints 
were assayed for white blood cell (WBC) count and immunophenotyped for 
CD3, CD4, CD8 and in the second infusion, V-beta 16 and an irrelevant 
control, V-beta 17. Viral loads are expressed as RNA copies/ml. Percentages 
are expressed in brackets.
restimulated assays). Figure 17 shows the ex vivo activity of CTL before and after 
infusion. Figure 18 shows the restimulated CTL activity present in Patient 008 
before and after cell transfer. Surprisingly, even before transfer, there was 
considerable activity (30% specific lysis) in response to target cells bearing the Gag 
p24 peptide.
Figure 17: Ex vivo “fresh” CTL activity post-first infusion
PBMC obtained from Patient 008 just before (Time 0) and at 1 hr and 20 hours 
after the adoptive transfer of CTL Clone 28 (HLA-B8 restricted. Gag p24-13) were 
tested immediately ex vivo for CTL activity against autologous LCL coated with the 
indicated peptides. Squares represent Clone 28 and diamonds represent Clone 20.
Figure 18: Restimulated CTL activity post-first infusion
PBMC obtained from Patient 008 before transfer (diamonds) and at 1 hr (squares), 
4 hours (triangles) and 7 days (circles) after transfer were restimulated with 
autologous LCL coated with peptide Gag p24-13 and tested after 14 days of culture 
in the presence of IL-2.
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Subsequent Infusions (Second and Third Infusions)
The lytic activity of the clones prior to the second and third infusions is shown in 
Figures 19 and 20. As with the first infusion, similar data were obtained for ex vivo 
and restimulated assays following the second and third infusions (Figures 21, 22 and 
23) despite the increased numbers of infused CTL. No effect was seen on viral load 
following any infusions. Following the second infusion, PBMC were stained for V- 
beta 16 (the clonal TCR on the infused Clone 28) and an irrelevant V-beta 17. In 
accordance with the number of cells infused, the proportion of V-beta 16 positive 
cells rose from 1.8% to 2.4% while the proportion of V-beta 17 cells remained at 
5.4%.
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Figure 19: Patient 008 Clone 18 CTL activity pre-second infusion
Four cry ©preserved vials of Clone 18 were thawed, restimulated and tested for 
cytotoxic activity with autologous B cells coated with 1 pM peptide (GGKKKYKL).
Figure 20: Patient 008 clones pre-third infusion
Cytotoxicity of Clones 20 (circles, HLA-A2 pol), 18 (squares, HLA-B8 Gag 17-3) 
and 28 (triangles, HLA-B8 Gag 24-13) on the day of infusion. Target cells were 
autologous LCL coated with 1 pM of relevant peptide.
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Figure 19: Patient 008 Clone 18
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Figure 21: Ex vivo CTL activity post-second infusion
PBMC taken from Patient 008 before transfer Oh) and at 1 hr, 20 hrs and 4 days 
after transfer were tested immediately ex vivo with autologous B-cell targets coated 
with Gag p24-13 (diamonds) or Gag pl7-3 (squares).
Figure 22: Restimulated CTL activity post-second infusion
PBMC taken from Patient 008 before transfer and at 1 hr, 4 hrs and 14 days after 
transfer were restimulated with Gag p24-13 (diamonds) or Gag p i7-3 (squares) and 
tested after 14 days of culture medium containing IL-2.
Figure 23: Ex vivo and restimulated CTL activity post-third infusion
PBMC taken from Patient 008 before transfer (Ohr) and at 2 hours and 6 days after 
transfer were tested immediately ex vivo with autologous B-cell targets coated with 
Gag p24-13 (circles), Gag pl7-3 (squares) or Pol (triangles). PBMC taken from 
Patient 008 before transfer and at 2 hours after transfer were stimulated Gag p24- 
13 (circles), Gag pl7-3 (squares) or Pol (triangles) and tested after 14 days of 
culture in medium containing IL-2.
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Figuré 21: Patient 008 Second Infusion Ex Vivo CTL Assays
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Figure 22: Patient 008 Second Infusion Restimulated CTL Assays
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Expression of Fas
Control of lymphocyte populations, including CTL is dependent on the regulated 
expression of Fas and T-cell activation results in the upregulated expression of both 
Fas and Fas ligand. To confirm expression of Fas, Clone 28 was stained with mouse 
anti-Fas FTTC (Figure 24).
Fas-Mediated Apoptosis
Because Clone 28 expressed Fas we were interested in determining if the clone was 
senistive to Fas-mediated death in vitro. Clone 28 was incubated with an agonistic 
monoclonal antibody specific for Fas and cell death was assayed by trypan blue 
staining. CTL incubated with antibody were triggered to undergo apoptosis and 
this was demonstrated to be dependent on the expression of Fas as addition of 
soluble Fas fusion protein was able to prevent cell death (Table 12). Addition of IL-2 
to the medium also appeared to prevent apoptosis of CTL.
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Figure 24: Fas expression by Clone 28
FL1-H
Clone 28 was removed from cell culture and stained with 
anti-human Fas monoclonal antibody conjugated to FTTC 
or mouse isotype control conjugated to FTTC
Table 12: Fas-mediated death of Clone 28
With IL-2  Without IL-2
Anti Fas alone % Live % Dead % Live % Dead
100 ng/ml 88 13 50 50
50 ng/ml 100 0 56 44
10 ng/ml 100 0 43 57
Anti-Fas + Fas-antagonist
100 ng/ml 100 0 77 23
50 ng/ml 81 19 92 8
10 ng/ml 93 7 86 14
Clone 28 (HLA B8-restricted) was incubated with anti-Fas antibody 
(agonist) alone or with Fas-antagonist (Fas fusion protein) in the presence or 
absence of human IL-2 (25 cetus units/ml). Viable cells were determined by 
trypan blue exclusion after 16 hours.
Discussion
The results above show clearly that fastidious planning is necessary for the 
successful implementation of adoptive transfer. CTL clones must be developed 
which possess good lytic activity and good growth potential. The clones must be 
carefully characterized to ensure they are what they seem to be. The clones must be 
grown in an absolutely sterile environment and tested carefully (although 
retrospectively) for bacterial, fungal or viral contamination.
Perhaps the most difficult aspect of this form of therapy is the expansion of CTL 
clones. Previous methods employed in our laboratory, while sufficient to grow 
millions or even tens of millions of cells were inadequate for the large scale culture 
which was necessary. Clearly, the expansion of clones in plates is not practical from 
the point of view of labour and also the risk of contamination. Growing clones in 
flasks represents a good alternative. Cells appeared to grow optimally in T25 (25 ml) 
flasks, less well in T75 (200 ml) flasks and even less well in (600 ml) flasks. Because 
the maximal concentration of cells is generally around 1-2 million per ml, a single 
T25 flask containing 30 mis of medium will contain at most 60 million cells,
generally less. Therefore, to harvest 1000 million (10^) cells it would be necessary to 
use around 30 flasks for each clone. A good compromise is to grow the cells in 175 
flasks which yield close to 1 million cells per ml and contain 60 mis of medium. 
Thus, one need only manipulate around 15-20 flasks per clone. As can be seen both 
from the above data and from subsequent cell growth data presented in the next 
chapter, there is a learning curve associated with mass cell expansion. Although the 
methods used from one infusion to the next did not vary, the success with growing 
cells certainly did.
One aspect of cell growth which may be very important, is the dividing potential of 
the clone. The clones used for these experiments were first made in 1991 m d  had 
undergone an estimated 5-10 cell expansions in that time. The number of actual cell 
divisions may be much higher. Both anecdotal data from S. Riddell (personal 
communication) and my own observations, suggest that ideally, one should utilize
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"fresh" or "fresh-frozen" clones for large scale expansion. That is, one should clone 
CTL from the patients PBMC as early as possible, expand the clone once and 
cryopreserve many aliquots of this original expansion for subsequent expansion. 
These aliquots will only have been exposed to MHC-peptide or anti-CD3 twice since 
being removed from the circulation.
Of course, this does not take into account the fact that these antigen-specific clones, 
likely memory cells have been undergoing a massive cycles of mitosis in vivo as a 
result of exposure to HTV infected target cells. Nonetheless, "new clones" seem to 
grow better than "old clones". Perhaps physiological activation of the TCR is less 
damaging to the cells reproductive cycle than ex vivo (over)-stimulation using non- 
physiological doses of TCR ligand.
One mechanism by which CD8 cells may lose their divisive capacity is by the 
shortening of their telomeric repeats. All nucleated cells contain chromosomes, the 
ends (telomeres) of which are composed of hexameric nucleotide repeats. These 
repeating sequences are necessary for RNA initiated DNA replication during mitosis 
(Blackburn 1991). With each subsequent nuclear division, these hexameric repeats 
are lost and remain so unless the ends are re-synthesized by the enzyme, telomerase. 
I have looked at the telomere length of clone 28 retrospectively. Unfortunately, the 
proper control which would be clones freshly isolated from Patient 008, were not 
available. Thus I compared the telomere length of clone 28 to that obtained from 
three laboratory volunteers. The telomere lengths visualized were 11-12 kilobases 
and did not differ between Clone 28 and the three voluteers (all similar in age to 
Patient 008).
If telomere length is actually shortened significantly in the CTL clones, this implies 
not only that they may be difficult to expand ex vivo, but that they may have a 
limited efficacy in vivo following adoptive transfer. Ideally, the transferred memory 
cells would expand upon contact with antigen and carry out their effector function
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over many cycles of replication. This may not be the case with cells that have been 
over-expanded.
Another factor which may determine the efficiency and efficacy of the clones in 
vivo is the cytokine milieu and lymphoid architecture in vivo. As discussed in the 
introduction, the bulk of HIV-infected cells reside in the reticulo-endothelial organs, 
in particular the lymph nodes. In the lymph nodes, the lack of CD4 cells, quite 
pronounced in a patient with a CD4 count of 20/pl may result in a physiological 
lack of EL-2. Without EL-2 the transferred cells may not survive. In addition the 
architecture of the lymph nodes in advanced HTV disease is generally aberrant 
perhaps preventing proper lymphocyte re-population or preventing normal 
lymphocyte-lymphocyte contact.
It may not be coincidental that thus far, the successful use of adoptive CTL transfer 
in humans has been in recipients who had been preconditioned either with radiation 
or with chemotherapy. Ablation of dividing cells may produce an environment 
more receptive to repopulation of infused cells. Certainly, adoptive transfer 
experiments conducted in mice and rats and published many years before human 
adoptive transfer frequently raised the concept of "space" ((Makela and Mitchison 
1965, Makela and Mitchison 1965); Cochame et al, 1962; Dixon et al, 1963) as a 
necessary precondition for optimal adoptive therapy. Space was generally created 
by prior irradiation of the recipient animal. This was hypothesized to produce a 
depletion of lymphocytes in the peripheral lymphoid organs which could then be 
more readily replaced by transferred cells. Alternatively, Celada has argued that a 
natural barrier to transferred cells exists and that irradiation may remove this barrier 
(Celada 1967). Bell et al transferred thoracic duct lymphocytes with a memory T- 
cell response to HSA into both normal and irradiated congeneic rats (Bell and 
Shand 1975). In one experiment, they removed lymphocytes from potential 
recipients through a thoracic duct fistula in an attempt to create cellular space in a 
non-irradiated host. By measuring HSA antibody response, they found that the 
lymphocyte depleted recipients had no greater antibody responses than normal
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recipient rats. In contrast, irradiated recipients had one to two log increases in 
antibody responses when compared to normal rats. Moreover, by comparing 
adoptive therapy of similar cells into young (3 week old) rats and comparing them 
to older (6 month old) rats, they showed that young recipients had antibody 
responses greater than normal older rats and in the range of irradiated recipients. 
Thus, there seems to be a factor present in older animals which limits reconstitution 
by infused memory cells. This is partially supported by the experiences of bone 
marrow transplantation where younger recipients generally fare better.
Hematopoeitic stem cells, referred to in stem cell therapy as colony forming units 
are pluripotent cells which are able to reconstitute the bone marrow of a 
preconditioned host. Memory cells, in contrast are mature, differentiated cells which 
have undergone numerous cell divisions in vivo and in the case of adoptive 
immunotherapy, ex vivo. Thus it is somewhat surprising that peripheral CD4+ 
lymphocytes with a memory phenotype have be shown to be capable of dividing up 
to 56 times in vivo following transfer into nude mice, a number of potential 
divisions similar to that of stem cells (Rocha, et al. 1989). However, the replicative 
potential of CD8+ cells appears to be lower and estimates are that they are able to 
double up to 17 times after transfer (Miller and Stutman 1984).
The replicative ability of adoptively transferred lymphocytes has been examined 
many times. Miller et al transferred limiting numbers of splenic cells into mice which 
had been thymectomized, lethally irradiated and reconstituted with T cell-depleted 
bone marrow. In this model, repopulation of helper and cytotoxic T-cells occurred 
up to 20% of normal although these cells appeared to be sufficient to protect 
animals from infection and behaved normally in both CTL and proliferation assays. 
Similarly, nude rats reconstituted with syngeneic thoracic duct lymphocytes 
exhibited a stable and permanent expansion of functional T-cells for at least 2 years 
following transfer (Bell 1979). It is worth noting however, that in most experiments, 
adoptive transfer of undepleted spleen cells was done. Thus, it is still unclear 
whether a co-transfer of CD4+ cells is necessary to positively influence the growth
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of CTL. In patients with advanced HTV, this may be a critical point, as there may be 
insufficient IL-2 production by remaining CD4+ cells or indeed insufficient 
repertoire of CD4+ cells to maintain growth of infused CTL.
In addition, the nature of the transferred cells may also influence its efficacy in vivo. 
Berzofsky has shown that cells cloned using a high concentration of MHC-peptide 
have a lower avidity for target cells and compare unfavourably with high avidity 
cells in their ability to clear a virus infection in mice. In later cloning experiments, I 
lowered the peptide concentration for cloning from lOOpM to IpM or less and 
found empirically that the killer activity of the clones was improved. In vitro, the 
peptide concentration on the surface of the cells may be several orders of magnitude 
lower than the concentration on target cells used for in vitro chromium release 
assays. Cloning and culturing CTL using high concentrations of peptide may select 
for relatively low affinity clones which may not possess significant in vivo activity.
Finally, the expression of Fas on the CTL clones may provide another means by 
which HIV-infected cells are protected. We have described a phenomenon known as 
"back-killing" by which SIV-infected cells, instead of behaving as passive target cells, 
actually kill incoming CTL by engaging Fas on their cell surface (Xu, et al. 1997). 
HTV infected cells also express Fas ligand and most of the CTL clones which I have 
tested express Fas. It is possible that when the HIV-specific CTL home in on their 
Fas-ligand expressing targets, they are activated to undergo apoptosis. In particular, 
since IL-2 appears to protect lymphocytes from undergoing apoptosis, the lack of 
CD4 cells in this patient may render the CTL more susceptible to back-killing. We 
have attempted to address this mechanism by a simple in vitro experiment. Clone 
28 which expresses Fas (Figure 24) and was infused into Patient 008 was washed 
and placed in RIO without IL-2. Timing of the experiment is important because 
clones do not survive for more than a few days without IL-2. Cells were placed in 
24 well plates containing only RIO or RIO plus a Fas agonist or RIO plus a Fas 
agonist and Fas antagonist. The results in Table 12 show that anti-Fas can indeed kill
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the Fas-expressing clone. Moreover, this killing is specific since it is blocked by the 
Fas antagonist and the clone is protected from apoptosis in the presence of IL-2.
In summary, there are two major obstacles to overcome in order for adoptive 
transfer therapy to become successful. These include developing the necessary 
infrastructure and two, understanding the complex biology of CTL-target 
interaction in vivo. In the case of HIV infection, the multitude of possible 
explanations for the inefficacy of adoptive transfer need to be examined and either 
refuted or endorsed. In the next chapter, we hope to shed further light on these 
mechanisms.
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CHAPTER FOUR
Adoptive Transfer Of Autologous HIV-Specific CTL To A Patient 
With A Relatively High CD4 Count
Introduction
In Chapter One we discussed the successful use of adoptive CTL immunotherapy 
for the treatment of EBV and CMV disease in post-BMT patients (Riddell, et aL 
1992, Rooney, et al. 1995, Walter, et al. 1995), thus raising the possibility that 
treating HIV-infected patients in a similar fashion may be beneficial. However, the 
transfer of HIV-specific CTL lines or clones in HIV-infected patients, although safe, 
has so far produced only modest results (Koenig, et al. 1995, Lieberman, et al 
1997, Riddell, et al. 1996).
We have seen in Chapter Three that adoptive transfer of HIV-specific CTL to 
Patient 008, who had a CD4 count of around 20/ul and a relatively low virus load, 
also failed to impact upon virus load. As discussed in that chapter, there are a 
number of theoretical reasons why the advanced state of his disease may have 
affected the efficacy of the therapy. In summary, the three main arguments are:
1. A low CD4 count may hamper optimal CTL effector function because IL-2 is 
necessary both as a growth factor for CTL and for optimal CTL effector function. 
Thus, the presumed lack of physiological levels of IL-2 in the lymph nodes of a 
patient with advanced HTV, may prevent adoptively transferred cells from dividing, 
maturing and lysing infected targets.
2. Upon meeting infected cells, CTL may either form an MHC-peptide-TCR 
complex or a FasL/Fas bond resulting in target cell lysis. In addition, the two cells 
may form a reverse Fas-FasL bond (FasL on the target cell) triggering apoptosis of
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the CTL. As shown in Table 12, lack of IL-2 may predispose CTL to death by 
apoptosis and conversely, presence of IL-2 protects CTL from Fas-mediated death.
3. Finally, virus load may also play a role in stimulating the CTL to divide and 
respond. A relatively low virus load may lack sufficient quanddtes of antigen to 
activate CTL optimally. Thus, in a patient with a high CD4 count and a relatively 
high (and increasing) virus load, the adoptive transfer of autologous HIV-specific 
CTL may be more effective.
In this chapter we present data from a single infusion of HIV-specific CTL into a 
patient with a relatively high CD4 count and a relatively high virus load. Thus we 
have the opportunity to examine the effect of transferred cells in a milieu of high 
CD4 counts and possibly physiological levels of EL-2 production. In addition we 
examine the discrepancy between results obtained in human adoptive transfer 
experiments for EBV associated lymphoproliferative disease and the failure of 
transferred HIV-specific CTL to significantly reduce virus loads.
We have transferred two autologous CTL clones specific for epitopes derived from 
Gag and Pol to a patient with a high virus load and clinical disease. In order to trace 
the fate of the infused cells in vivo, we have used soluble MHC-peptide molecules 
(tetramers) specific for the TCR of one of the infused clones.
Methods
Study patient
Patient 868 is a white homosexual male (HLA-A*0201,A*2401,B*27,B*3501) 
who, upon recruitment, had been HTV positive for over 6 years. Despite previous 
episodes of Pneumocystis carinii pneumonia and recurrent Herpes simplex 
infections, at the time of transfer, he was well and his CD4 count was 430/pl. 
Despite this relatively high CD4+ count the patient was experiencing symptoms
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such as fatigue and sweats which were attributed to high viral load and had only 
partially been controlled by antiretroviral drugs. His medications included 
zidovudine, didanosine and prophylactic trimethoprim-sulfamethoxazole. Ethical 
approval was obtained from Central Oxford Regional Ethics Committee and 
informed consent from the patient.
Preparation and expansion of CTL clones
In contrast to Patient 008, whose results are described in Chapter 3, we were able to 
prospect!vely generate CTL clones from Patient 868. In theory, these clones should 
be more efficient than clones which were resuscitated from frozen stocks. CTL 
oligoclonal lines were produced by incubating fresh PBMC obtained from the 
patient with irradiated, autologous EBV-transformed lymphoblastoid cell lines (LCL) 
coated with peptides derived from Gag and Pol. Two CTL lines with lytic activity to 
HLA A*0201-restricted epitopes from Gag (pi7 residues 77-85, SLYNTVATL) 
and Pol (residues 346-354, VIYQYMDDL) were generated and used for establishing 
clones by limiting dilution. Large scale expansion of CTL is described in detail in 
Chapter 3. CTL were grown in T25 or T75 tissue culture flasks, each containing the 
T-cell clone, irradiated allogeneic PBMC and irradiated allogeneic LCL. TCR 
stimulation was provided by monoclonal anti-CD3 (OKT3, a kind gift from 
Orthoclone) and the culture medium was RPMH64O supplemented with 10% 
human AB serum, glutamine, penicillin and streptomycin. Cells were harvested and 
washed the day following setup and resuspended in medium containing recombinant 
IL-2 (50 cetus units/ml). The cells were divided periodically according to growth and 
harvested 12 days after TCR stimulation. Aliquots of cells and supernatants were 
sent for extensive microbiological testing to ensure sterility.
Cytotoxicity assays
Chromium-51 (Cr-51) release assays were as described. Autologous LCL were 
incubated with Cr-51, pulsed with 5 pM peptide and incubated with CTL. 
Supernatants were harvested after 4-5 hours and measured in a betaplate counter 
(Wallac).
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Anchored PCR
The anchored PCR method has been described previously. Oligo dT-primed cDNA 
was synthesized from RNA obtained from two million T cell. The primers used 
were, Poly-C anchor - 5 ’-gcattcagctgcggccgc(c) 14-3 ’ ; cpi-5’-
tgaccgcagtcgacagacttgtcactggatt-3’ ; cp2 5 ’-atactggagtcgacggagatctctgcttctgatg-3 ’.
Soluble MHC-peptide tetramers
MHC-peptide tetrameric complexes were produced as previously described. Purified 
HLA heavy chain and p-2m were synthesized using a bacterial expression system 
(pET R+D Systems). The heavy chain was modified by the deletion of the 
transmembrane/cytosolic tail and the addition of a C-terminal sequence containing 
the BirA enzymatic biodnylation site (anti-sense primer for HLA-A*0201 
5'gggggaagcttaatgccattcgattttctgagcttcaaaaatatcgttcataccaccaccggatccacatacaagcttac 
ggctcccatcttaaggtgaggggcttggg3\ Heavy chain, P2 microglobulin and peptide were 
refolded by dilution. The 45kD refolded product was isolated by FPLC, and then
biodnylated by BirA in the presence of biotin (Sigma), ATP (Sigma) and Mg^+ 
(Sigma). Streptavidin-phycoerythrin conjugate (Leinco) was added in a 1:4 molar 
ratio and the tetrameric product was concentrated to 1 mg/ml.
Flow cytometry . monoclonal antibodies and virus loads
The CTL clones were phenotyped by dual-staining with PE-conjugated and-CDS 
mAh (Dako) and FITC-conjugated anti-CD3 (Dako), anti-CD28 (Immunotech) or 
anti-Fas mAh. Labeled cells were analysed on a Becton Dickinson FACScan using 
Cellquest software. Negative isotype control mAbs were FTTC- and PE-conjugated 
mAbs of irrelevant specificity (Dako). CD4 and CDS cell counts were done in a 
clinical immunology laboratory by standard methods. The HIV plasma 
concentrations were determined using a commercial (Roche Amplicor) PCR assay.
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Apoptosis assay
To analyse apoptosis in vivo, PBMC obtained before or after infusion were stained 
with 3 pi of PE-conjugated A2 Gag-specific tetramer (1 mg/ml) at 4 °C for 30 
minutes. After two washes the cells were stained with 100 pi Annexin-V-Fluos 
(Boehringer Mannheim) for 15 min. To test whether the CTL clones were sensitive 
to FasL-induced cell death in vitro, 5 x 10$ CTL were co-cultured with a FasL
expressing cell line (1x10^ cells, 1A12, a gift from Dr. S. Nagata. Osaka) with or 
without soluble Fas-Fc fusion protein (20ug/ml) in a 48-well plate for 16 hours. 
Cells were dual-labeled with PE-conjugated CD8 and Annexin-V-Fluos and analysed 
by flow cytometry as described above.
Results
HIV-specific clones
Two HLA A*0201 restricted CTL clones were established from Patient 868. The 
first recognizes the immunodominant HLA A*0201 restricted epitope from Gag 
pl7-8, SLYNTVATL (Figure 25a) and the other recognises VIYQYMDDL an 
uncommonly seen epitope derived from Pol (Harrer et al). This particular epitope is 
interesting because it contains the active site (YMDD) of the HIV reverse 
transcriptase (Figure 25b) and any mutations affecting this active site should 
abrogate the replicative capacity of the vims. CTL responses to this particular 
epitope are much less common than for the "immunodominant" Pol epitope, 
ILKEPVHGV (Table 13). Peptide titration studies of the A2 Pol clone revealed 
cytotoxicity only in the presence of large concentrations of peptide (Figure 26) -  at 
1 pM of peptide, most of the specific lytic activity is lost. This may account for the 
fact that CTL to this epitope are infrequently detected.
The activity of the A2 Pol clone was also tested against a number of peptide 
variants described in the literature (Table 13). In contrast to Harrer et al, our clone
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Figure 25: Patient 868 CTL Clones for Adoptive Transfer
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The lytic activity of the A2 Gag and A2 Pol clones on the day of infusion. 
CTL were tested against autologous target cells coated with SLYNTVATL 
(circles, left panel) or VIYQYMDDL (circles, right panel). Squares indicate 
uncoated target cells.
Table 13: CTL responses to HLA-A*0201 restricted reverse transcriptase epitope
P I  2 3 4 5 6 7 8 9  10
RT 179 180 181 182 183 184 185 186 187 188 Harrer et al Thesis
r a v - in m V I Y Q Y M D D L ++ ++
PI variant T I Y Q Y M D D L ++ na
PI variant I I Y Q Y M D D L ++ na
PI variant E I I Q Y M D D I L - na
HIV-2 Rod I I I Q Y M D D I L + -
HIV-2 Rod I L I Q Y M D D I L na -
HTLV-1 T I L Q Y M D D I L - na
HTLV-2 T I V Q Y M D D I L - na
srv T L V Q Y M D D L - -
Lamivudine/3TC V I Y Q Y V D D L - na
Nevirapine V I C Q Y M D D L - -
The index peptide (VIYQYMDDL) from HTV reverse transcriptase (RT) and 
variants as listed above were tested for cytotoxic activity using the Patient 868 A2 
Pol-restricted CTL clone and the results were compared with previously published 
results using RT-specific clones (Harrer et al). ++ refers to > 50% specific lysis, + 
refers to 20-50% specific lysis and - refers to <10% specific lysis.
Figure 26: Peptide titration o f A2 Pol clone
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The lytic activity of Patient 868 derived A2 Pol CTL 
clone was assayed against peptide coated autologous 
LCL target cells incubated with decreasing 
concentrations of peptide (diamonds) or target cells 
with no peptide labelling (squares).
does not recognize the PI variants. In addition, antagonism was not demonstrated 
using variant peptides, TLVYQMDDI, VICQYMDDL, RJYMDDI or Pol index 
peptide, ILKEPVHGV.
Both the A2 Gag clone and the A2 Pol clone expressed CD3, CDS and Fas, but not 
CD28 (Figure 27). The A2 Pol clone apparently contained two populations of cells 
expressing CD3medium/CD8high and CD3high/CD8medium respectively. The 
specificity of both clones was characterized using soluble, biodnylated tetrameric 
MHC-peptide molecules. Dual staining of the A2 Gag clone with soluble MHC-Gag 
tetramer and anti-CD8 demonstrated specificity for HLA A*0201-restricted Gag 
peptide (Figure 28a). Attempts to stain clone 10 failed because the Pol-tetramer 
complex was unstable, most likely a consequence of the low affinity of the Pol 
epitope for HLA A*0201 (Figure 26). Thus, the complementarity determining 
region 3 (CDR3) of the clone was sequenced by anchored PCR in order to 
determine its V-alpha and V-beta sequences (Figure 28b). Of 18 transcripts 
sequenced, all contained the same CDR3 nucleotide segment corresponding to 
Va22/Ja9.11 and Vbl3.3/Jb2.3/Cb2 and providing evidence of clonality.
Adoptive transfer
The A2 Gag and Pol clones were grown to 1.1 x 10^ and 1.7 x 10^ cells 
respectively for adoptive transfer and the expanded clones were tested for cytotoxic 
activity the day before transfer (Figures 25a and 25b). The cells were infused into a 
peripheral vein over a period of 30 minutes. The transfer was well tolerated except 
for a single episode of chills and rigours approximately 4-6 hours following infusion. 
These subsided without the use of medications and the patient was subsequently 
well
CD4/CD8 and virus loads post-infusion
Table 14 shows the peripheral blood CD4 and CD8 lymphocyte counts and the 
virus load before and after adoptive transfer. Unexpectedly, no increase was
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Figure 28: Patient 868 Clone Specificity
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Table 14: CD4 and CD8 counts and virus load before and after infusion
Time 0 4-lhr +20hr +48hr +7d +14d +21d
CD4 (cells/pi) 
CD8 (cells/pl) 
Virus load 
(RNA copies/ml)
430
1720
31,000
440
1760
26,600
390
1600
49,300
490
2030
45,970
480
1910
63,500
510
2100
56,300
400
1810
ND
CD4 and CD8 counts were determined by flow cytometry and plasma viral 
load was measured using the Roche Amplicor assay at the time points 
indicated.
detected in the number of CD8+ cells one hour or 20 hours after infusion. There 
were no significant changes in the virus load following therapy.
Tracking Clone 19 in vivo
PBMC obtained from the patient before and after adoptive transfer were stained 
with the TCR-specific tetramer (which recognizes the TCR on the A2 Gag clone) 
and CD8-tricolour (Figure 29). Controls included studies using a B35 tetramer 
complexed with an HTV Env-derived peptide, which had not been infused. 
Tetramer-posidve cells accounted for 1.6% of CD8 cells in the patient before the
infusion, increasing to 2.2% after infusion. Given that 2.5 x 10$ staining events were 
measured at each time-point with the same reagents, this represents a real and 
substantial increase. This 37% increase in tetramer positive cells is approximately
what would be expected assuming total body CD8+ T-cells were 2 x 10 H pre- 
infusion, with 3.2 x 109 pre-existing tetramer-positive cells and an infusion of 1.1 x 
109 additional tetramer -positive cells. In order to determine the percentage of Gag- 
specific cells undergoing cell death, PBMC obtained from the patient were also triple 
stained with tetramer, CD8-tricolour and a marker of apoptosis, Annexin V-FTFC 
(Figure 30). In tetramer positive cells, the proportion of dead cells increased from 
29% before infusion to over 90% of cells 48 hours after infusion.
Fas ligand induced death of CTL clones
Because Clone 10 and Clone 19 expressed Fas and underwent apoptosis in vivo, we 
examined the susceptibility of the CTL to Fas-dependent apoptosis in vitro by 
incubating each clone separately with a Fas ligand expressing cell line, 1A12. Cell 
death was assayed by flow cytometry (Figure 31). CTL incubated with 1A12 were 
triggered to undergo apoptosis. This was demonstrated to be dependent on the 
expression of Fas as addition of soluble Fas fusion protein was able to prevent cell 
death.
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Figure 29: Tetramer-specific A2 Gag cells before and after infusion
PBMC taken from the patient at the indicated timepoints were stained with anti- 
CD8 triclour, A2 Gag-specific tetramer PE and a control, B35 Env-specific tetramer 
PE. The percentages shown represent CD8-positive/tetramer-positive cells.
Figure 30: Death of tetramer-specific A2 Gag cells in viva before and after infusion
The A2 Gag clone (before infusion) and PBMC obtained from the patient at the 
timepoints indicated were stained with anti-CD8 tricolour, Gag-specific tetramer PE 
and Annexin V. The histograms represent Annexin V staining of the CD8- 
positive/tetramer-positive cells.
Figure 31: Fas-dependent death of A2 Gag clone
A2 Gag and Pol clones were incubated separately with medium alone or with a Fas- 
ligand expressing cell line, 1A12 with or without Fas fusion protein (FasFc). CD8 
positive cells were gated and examined for Annexin V staining.
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Discussion
The utility of adoptive transfer for the treatment and prevention of EBV and CMV 
infections in patients immunosuppressed following BMT (Papadopoulos, et al. 1994, 
Rooney, et al. 1995, Walter, et al. 1995) suggested that a similar strategy might be 
useful in HIV and early reports involving the infusion of non-specific, autologous 
CD8+ cells to HIV-infected patients showed the general method to be safe although 
ineffective for reducing viral replication (Ho, et al. 1993, Klimas, et al. 1994). 
However, the subsequent transfer of HIV-specific CTL lines and clones have 
produced only modest outcome or possibly detrimental outcomes (Koenig, et aL 
1995, Lieberman, et al. 1997, Riddell, et al. 1996).
We have examined the in vivo fate of transferred CTL to explain the apparent lack 
of in vivo activity. The number of cells we infused represented around 1% of the 
total CD8+ cells present in the patient - a frequency at the high end of the spectrum 
in HIV-positive subjects and one that would be expected to reduce viral replication 
measurably. However, despite attempts to optimise therapy, the infusions failed to 
reduce virus load. In an attempt to explain the lack of efficacy, we traced the infused 
cells using soluble, tetrameric HLA A*0201-Gag molecules, which are able to stain 
specifically the infused Gag clone by binding to its clonotypic TCR. A short-lived 
increase was seen in the clonal cells following infusion, with the number of tetramer- 
positive CD8 cells rising from 1.6% to 2.2%. By staining the PBMC with and-CD8, 
tetramer and Annexin V, we determined that the clonal cells were undergoing rapid 
cell death, with over 90% of tetramer-positive cells dying within 48 hours.
In mice, the adoptive transfer of CTL is effective in controlling infection with 
influenza and LCMV, consistent with the survival and expansion of the infused cells 
(Baenziger, et al. 1986, Lukacher, et al. 1984, Yap, et al. 1978). The frequent pre­
treatment of mice with irradiation apparently facilitates expansion of these cells, 
suggesting that removal of lymphocytes provides a stimulus for re-population of 
lymphoid tissue (Bell and Shand 1975). In this regardait may be significant that 
successful adoptive transfer in humans has been limited so far to BMT recipients,
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who would have received prior chemo- or irradiation therapy. Moreover, cell 
transfer in BMT recipients are performed in a setting of an actively regenerating 
immune system, which is not the case in AIDS patients or recipients of solid organ 
transplants. In addition, the lymphocytes which are transferred in murine 
experiments are often resting spleen cells; in contrast, we used antigen-stimulated, 
cultured CTL which may possess different characteristics in vivo due to the non- 
physiological expansion process. The development of the mature, stimulated 
phenotype seen in our clones, characterized by upregulation of Fas and absence of 
CD28 expression, may be a result of overstimulation of HIV-specific lymphocytes 
both in vivo (prior to culture) and in vitro. The rapid and prolonged expansion 
which these cells undergo may render them susceptible to premature apoptosis, 
particularly in the absence of sufficient IL-2. The rapid turnover of HIV-specific 
CTL in vivo was confirmed by our observation that prior to transfer, 29% of the 
Gag-specific cells were undergoing cell death. The infusion of roughly 30% more 
cells did not alter the anti-viral response; instead, a higher percentage of tetramer- 
positive cells underwent apoptosis following infusion, implying that a cascade of 
antigen-specific cell death was triggered. Follow-up of the patient forty days after 
cell-transfer indicated that the number of Gag-specific CTL had not returned to pre- 
treatment levels (data not shown) and suggests that the lost CTL were not 
replenished by expansion of naive cells.
Interestingly, in a previous trial of adoptive transfer, in which a single Nef-spedfic 
clone was infused to a patient with AIDS, the clone appeared to drive the selection 
of viruses containing mutations in the targeted Nef epitope. The selection of escape 
mutants in this setting implies that the infused CTL survived in vivo and exerted 
pressure on HIV-infected cells. However, in that trial, some of the cell infusions were 
accompanied by very large doses of IL-2, raising the possibility that the survival of 
CTL in vivo is contingent on CD4+ T-cell help, predominantly through EL-2: this 
may be absent or dysfunctional in HIV-infected patients. The suggestion that CTL 
require proper CD4+ cell function for optimal activity is supported by data in mice 
and humans. In mice with a null mutation of CD4, infection by lymphocytic
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choriomeningitis virus (LCMV) leads to rapid disappearance of anti-viral CTL and 
poor control of viral replication (Battegay, et al. 1994). Similarly, in 
immunosuppressed patients whose anti-CMV cellular immunity was restored by 
adoptive transfer, CTL activity correlated with the level of CMV-specific CD4+ T- 
cells (Riddell and Greenberg 1995, Walter, et al. 1995). This hypothesis is also 
supported by recent data which show that HTV-l-specific proliferative responses to 
p24 were inversely related to viral load (Rosenberg, et al. 1997).
The control of lymphocyte lifespan is thought to be dependent upon the regulated 
expression of the TNF-receptor family molecule, Fas, which induces a signal cascade 
leading to cellular apoptosis upon activation by Fas ligand (Lynch, et al. 1995). We 
and others have shown that SFV and HIV-infected cells upregulate FasL enabling 
them to reverse-kill antigen-specific CTL in a Fas-dependent manner (Xu, et aL 
1997). We now confirm this observation using human cells in vitro by 
demonstrating that a Fas-ligand-expressing cell-line can kill HIV-specific CTL clones 
in a Fas-dependent manner. It is unclear whether the EBV and CMV-specific CTL 
clones previously used in BMT patients were expressing Fas, although this would be 
expected given the in vitro expansion protocols. In that case, it would suggest that 
EBV or CMV-infected cells do not upregulate FasL in the same manner as HIV or 
SFV. However, it may be worthwhile to investigate this mechanism further for trials 
of adoptive therapy in other situations, including malignant disease, where Fas 
ligand is frequently upregulated.
Because human trials of adoptive cell transfer in HTV are laborious and infrequent, 
the generality of these finding will need to be confirmed by different groups. The 
finding that HIV-specific CTL undergo apoptosis following adoptive transfer will 
need to be confirmed. Ideally, controls would be added to include adoptive transfer 
of HLA-mismatched CTL or adoptive transfer of CTL to healthy controls. 
However, at the moment these experiments could not be easily conducted. 
Subsequent trials should take into account the vulnerability of cells cultured in vitro 
to apoptosis and employ means for quantifying their survival in vivo. These data
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also suggest co-infusion of IL-2 may increase the survival of CTL. Engineering 
apoptosis-resistant antigen-specific CTL may circumvent the obstacle, but the 
success of this strategy depends upon better elucidating the mechanisms of cell 
death in vivo.
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Summary Of Adoptive Transfer Experiments
In summary, we have conducted three human adoptive transfer experiments:
1. Adoptive transfer of syngeneic lymphocytes from an HIV-uninfected individual 
to his HTV-infected identical twin. We have shown that:
i) The TCR repertoire of CD8+ cells is grossly disturbed in AIDS.
n) CD8+ V-beta expansions may occur early or late following adoptive
transfer of lymphocytes.
iii) Expansions of CD4 and CD8 cells occur in vivo and are maximal at 
around 6 weeks following transfer.
2. Adoptive transfer of autologous HIV-specific CTL to an HIV-infected patient 
with a low CD4 count. We have shown that:
i) Adoptive transfer of autologous HIV-specific CTL is feasible and safe.
ii) No changes to virus load occur following CTL transfer.
iii) Restimulated HIV-specific CTL responses are cyclical in nature.
iv) Expanded CTL express Fas and are susceptible to Fas-mediated apoptosis.
v) IL-2 protects cultured CTL from Fas-induced apoptosis.
3. Adoptive transfer of autologous HIV-specific CTL to an HTV-infected patient 
with a moderate CD4 count. We have shown that:
i) Despite a moderate CD4 count and a high virus load, transfer of HTV- 
specific CTL does not reduce viral burden.
ii) HIV-specific CTL rapidly undergo apoptosis in vivo following adoptive 
transfer.
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iii) HIV-specific CTL can be triggered to undergo Fas-mediated apoptosis 
using a Fas ligand expressing cell line.
Adoptive transfer of CTL for the therapy of AIDS has not yet proven useful and 
does not justify the intensive labour required. A better understanding of the 
mechanisms of in vivo lymphocyte repopulation is needed to circumvent the 
problem of cell survival. In particular, it will be necessary to study more closely 
animal models of lymphocyte repopulation with particular regard to the factors 
which mediate peripheral positive selection of lymphocytes and lymphocyte 
expansion. The phenotype of the adoptively transferred cell will also require study 
to determine if memory CTL are capable of longterm expansion. These in vivo 
factors have important implications not only for HTV and AIDS but for the adoptive 
cell therapy of tumours and other infectious diseases where prior ablation or 
suppression of lymphoid cells is not a pre-condition. In addition, by identifying the 
mechanisms which trigger lymphocyte death, we may be able to genetically modify 
cells to resist apoptosis. For instance, some investigators have attempted to transfect 
virus-specific CTL with a chimeric protein vector expressing the cytoplasmic 
domain of IL-2 with the extracellular portion of the GM-CSF receptor -  the 
advantage of this approach is the option of infusing GM-CSF to patients in order to 
stimulate IL-2 secretion from CTL and hopefully obviate the need for functional 
CD4 helper cells. Other groups have transfected T cells with “universal T cell 
receptors” which couple the extracellular domain of CD4 or other HTV recognizing 
domains with the TCR cytoplasmic domain in an attempt to bypass MHC restriction 
(Yang, et al. 1997). In this latter approach, the therapeutic efficicacy of these cells 
will likely also depend on the in vivo availability of lymphocyte growth factors.
Despite its limitations for AIDS, CTL therapy may prove useful in some other 
settings including the control of Herpes group viruses other than EBV and CMV. 
For instance, HHV-8 is a gammaherpesvirus which share with EBV the propensity 
to cause tumours in immunosuppressed individuals. These tumours include Kaposi’s 
sarcoma and body cavity lymphomas. Cultivation of HHV-8 specific CTL in vitro
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may offer an alternative therapy for these diseases since these diseases are normally 
controlled by the intact immune system.
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